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The introduction and widespread use of highly active antiretroviral therapy 
(HAART) in the past decade has changed the profile of HIV/AIDS epidemic. Marked 
decreases in mortality and morbidity have been reported in low- and high-income 
settings. Recently, significant relative increases in non-AIDS-associated conditions in 
HIV-infected individuals have been reported in developed countries. 
In Brazil, where access to HAART has been universal for all eligible patients 
since 1996, a steep decrease in mortality among HIV/AIDS patients has also been 
documented, but the rates have been stable since 1999. So far, no data have been 
available about the pattern of non-HIV-related mortality in these patients. In these 
studies, we assessed temporal changes in causes of death among HIV-infected 
patients in Brazil. 
In the first paper using Brazilian national mortality data, we demonstrate that, 
between 1999 and 2004, the odds of having conditions not usually considered to be 
related to HIV-infection among individuals who had HIV/AIDS listed on their death 
certificate significantly increased over time. Specific diseases that increased were 
cardiovascular diseases and diabetes mellitus. 
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 In the second paper, we studied temporal trends in cause of death in a cohort of 
HIV-infected patients in Rio de Janeiro. Results showed an increase of non-AIDS 
causes of death and a decrease of AIDS causes of death in HIV-infected patients, 
which appeared to be driven by an aging of the population. 
This cohort study was facilitated by a linkage algorithm that was developed to 
recover vital status from patients lost to follow-up. In a third paper that validated the 
algorithm, sensitivity and specificity were found to be 95% and 100%, respectively. In 
addition, the use of the algorithm led to a 50% increase in the observed mortality rate. 
These findings have major public health and programmatic implications for 
developing countries that are scaling-up access to antiretroviral therapy. In the HAART 
era, HIV infection has become a manageable disease and is now associated with an 
increase in chronic illness. Public health measures that are not normally targeted to this 
population need to be included in their regular care, such as smoking cessation, lipid-
lowering drugs, and hypertension control. 
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 1.0 BACKGROUND AND LITERATURE REVIEW 
The introduction and widespread use of highly active antiretroviral therapy 
(HAART) in the past decade deeply changed the profile of HIV/AIDS epidemic. 
Marked decreases in mortality and morbidity have been reported in both low- and 
high-income settings [1-4], turning a deadly disease into a manageable chronic 
condition. One immediate consequence of the increased survival of HIV/AIDS 
patients is allowing more time at risk for causes of death that may or may not be 
related to the underlying infection.  
Several studies in developed countries both population-based and cohorts 
have documented these changes, showing that although HIV/AIDS-related causes 
of death remain at the top of the list, other conditions, including Diabetes Mellitus 
(DM), cardio-vascular diseases (CVD), cancer, liver and renal diseases have been 
increasingly reported in HIV-infected individuals [5-9]. Using combined information 
on HIV/AIDS surveillance with vital statistics data in New York City, Sackoff et al. 
[6] showed an increase in the proportion of non-HIV/AIDS-related causes of death 
from 19.8% to 26.3% between 1999 and 2004, with CVD ranking second among 
them and DM reaching 4.4% among women. In another population-based study in 
the U.S., Selik et al., showed that patients who had HIV/AIDS mentioned on the 
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 death certificate, had CVD increased from 4% to 7.7% from 1987 to 1999, with a 
steeper increase between 1996 and 1999 [9].  
Similar trends have also been documented in cohort studies. In the 
CASCADE Collaboration, CVD and DM as a group increased from 1.3% in the pre-
HAART era to 4.3% in post-HAART era [7]. In the HIV Outpatient Study, Palella et 
al. [8] showed that non-HIV/AIDS-related causes of death increased from 13.1% to 
42.5% between 1996 and 2004, with CVD being the leading cause of death in this 
group in 2004. Crum et al., studying an HIV cohort of U.S. military beneficiaries, 
also showed increases in cardiac disease (from 8% to 22%) and DM (from 0% to 
3%) being listed on the death certificates in the pre- and post-HAART era, 
respectively [5]. In a more recent paper, Lau et al. showed that the risk of non-HIV-
related deaths was even higher than HIV-related causes for individuals with CD4+ 
counts greater than 200 cells/mm3 in the HAART era [10]. 
Even though some controversy exists about the association between the 
use of antiretroviral therapy (ART) and cardiovascular diseases [11], growing 
evidence has been pointing to increased risk of ART use, especially protease 
inhibitors (PI) with cardiovascular events.  
A possible contributing role of uncontrolled HIV replication on the risk of 
non-HIV-related deaths has also been suggested [12], even though evidence so far 
only corroborates this finding for liver-related disease death rates [13] and hepatitis 
C virus coinfection death rates [14]. 
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 1.1 ROLE OF ART IN CVD RISK FACTORS 
After the description of peripheral lipodystrophy, hyperlipidemia and insulin 
resistance in patients taking PI-containing ART in 1998 [15], known risk factors for 
CVDs, several studies have shown an association between ART and dyslipidemia, 
especially PI-containing regimens [16-21]. 
In a retrospective study of 200 patients, 40 patients were treated with dual 
nucleoside reverse transcriptase inhibitors (NRTI) plus saquinavir alone, 40 
patients received NRTI and indinavir alone, 40 subjects received NRTI plus 
ritonavir alone, 40 patients received NRTI with (13 cases) or without (27 patients) 
nonnucleoside reverse transcriptase inhibitors (NNRTI), and 40 patients did not 
receive antiretroviral therapy, Manfredi et al. [17] showed that 
hypertrygliceridaemia was significantly more frequent and severe in patients taking 
ritonavir vs. indinavir (P<0.001), and in subjects given indinavir vs. all remaining 
patients (either treated or not) (P<0.001), while isolated saquinavir use was 
associated with higher triglyceride levels than NRTI-NNRTI treatment alone, or no 
antiretroviral therapy (P<0.03). 
Results from the Data Collection on Adverse events of Anti-HIV Drugs 
(D:A:D) study [16] showed similar results, with increased prevalence of elevated 
total cholesterol (> 6.2 mmol/l) observed among subjects receiving an NNRTI but 
no PI [odds ratio (OR), 1.79; 95% confidence interval (CI), 1.45–2.22], PI but no 
NNRTI (OR, 2.35; 95% CI, 1.92–2.87), or NNRTI + PI (OR, 5.48; 95% CI, 4.34–
6.91) compared to the prevalence among ART-naïve subjects. 
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 High Framingham scores with HAART use were found in a Norwegian 
cross-sectional study with 714 patients [19]. The prevalence of a 10-year estimated 
CHD risk of >20% was 11.9% in patients on HAART compared to 5.3% in controls 
(P=0.004). The same group also studied differences in the components of the 
metabolic syndrome comparing HIV-infected patients with or without HAART, 
compared to HIV-negative individuals [20]. They found that in non-overweight 
subjects the prevalence of the metabolic syndrome was 15% in HAART-treated 
patients, 2% in HAART-naïve (p=0.019) and 2% in controls (p=0.020). The 
prevalence of insulin resistance in non-overweight subjects was also higher in 
HAART treated than in controls, 39% vs 18% (p=0.012). In non-overweight patients 
with lipodystrophy the metabolic syndrome was diagnosed in 21% and insulin 
resistance in 49%. 
Cheseaux et al. showed that hyperlipidemia was also present in HIV-
infected children treated with PI-containing regimens [21]. Plasma cholesterol 
levels were significantly elevated in those taking PI, being more pronounced for 
those given ritonavir (from 3.3 ± 0.7 mmol/L to 6.3 ± 2.8 mmol/L; p=0.03) than for 
nelfinavir (from 3.0 ± 0.7 mmol/L to 4.9 ± 1.0mmol/L; p<0.001). Cholesterol levels 
exceeded 10.0 mmol/L in 6% of PI-treated children and culminated at 13.8 mmol/L. 
Even though the authors conclude that these changes have minimal risk for heart 
disease development in children, it corroborates the effect of PIs over lipid 
disorders. 
Also of note is the fact that HIV infection per se may be involved in lipid 
profile changes in infected individuals, and that treatment may have a modulation 
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 effect over it. Riddler et al. demonstrated in 50 men form the MACS study that 
significant declines occurred in total (TC), low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) cholesterol levels after HIV seroconversion. Treatment 
with HAART elevated the levels LDL back to pre-seroconversion levels, had no 
effect on HDL and increased TC to a mean excess of 20mg/dl in three years. Even 
though the authors conclude that these levels of TC are expected, the study lack 
power to make more refined comparisons [18]. 
Even though still controversial, other risk factors for CVD include DM [22] 
and hypertension [23]. 
1.2 ROLE OF ART IN CVD 
Table 1.1 describes 11 articles on the relationship between ART and PI-
containing ART use and risk of cardiovascular diseases. Even though the first 
three studies listed failed to establish an association between PIs and 
cardiovascular disease [24], heart disease [25] and myocardial infarction (MI) [26], 
respectively, there is growing evidence that ART and especially PI-containing ART 
in fact increase the risk of such events. Two studies from D:A:D established the 
correlation of ART and cardiovascular events [27] and also PIs and MI [28]. The 
results point to an increased risk of these conditions of about 26% per year of 
exposure. Two other studies pointed out the association between PI use and MI, In 
the French Hospital Database [29], PI was associated with a relative hazard of 
2.56, and in the HOPS with a hazard ratio of 6.5, despite the fact that they had 
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 relatively low power to detect the effect. Heart disease was also shown to be 
associated both with ART [30] and PI [31] use. In the former study PI use doubled 
the risk of heart disease in young patients, whereas in the latter both coronary 
disease and MI had significantly higher incidence in patients taking PI. Data from 
the HIV Insight study alone [32] showed an association between PI intake for more 
than 60 days and cardio- and cerebro-vascular events (adjusted HR=1.71, 
95%CI=1.08,2.74). In another study combining data from this study with the Athena 
study [33] use of PI was found to be associated with MI (HR=1.19, 
95%CI=1.01,1.40). 
Table 1.1. Studies of the association between PI and CVD 
Study 
No. Patients 
(follow-up) 
Events 
Risk with 
PIs? 
Main Findings Reference 
Veterans 
administration 
cohort 
36 766 (mean: 40 
months) 
1 207 
admissions for 
CCVE 
No 
No association between PI 
(HR=1.23, 95%CI=0.78,1.93) or 
NNTRI (HR=0.88, 
95%CI=0.63,1.22) 
[24] 
Kaiser 
Permanente 
4 159 (median: 4.1 
years; mean: 3.6 
years) 
72 
hospitalizations 
for CHD events 
No 
No significant increase in risk 
before and after PI (6.2 vs. 6.7 
events/1000py) 
[25] 
Meta-analysis 
of 30 RTs 10 986 (variable) 29 MIs  
No 
PIs did not increase risk relative 
to NRTIs (RR=1.69, 
95%CI=0.54,7.48) 
[26] 
California 
Medicaid 
cohort 
28 513 (median: 
2.25; mean: 2.50) 
1 360 CHD 
events 
NS 
ART treatment in young (18-33 
years) individuals increased risk 
for CHD (RR=2.06, 
95%CI=1.42,2.99) 
[30] 
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 Table 1.1. Continued: 
 
French 
hospital 
database 
34 976 (mean: 30.2 
months; median 
without MI:33 
months; median with 
MI: 28 months) 
60 MIs Yes 
PIs associated with higher risk of 
MI (RH=2.56, 95%CI=1.03,6.34) 
[29] 
Italian cohort 1 551 (median: 36 
months 
25 CHD events Yes 
PI-containing regimens 
associated with higher incidence 
of CHD (9.8/1000py vs. 
0.8/1000py, p<0.001) and MI 
(5.1/100py vs. 0.4/1000py, 
p<0.001) 
[31] 
HOPS 5 672 (mean: 3.2 
years) 
21 MIs Yes 
PI associated with higher risk of 
MI (OR=7.1, 95%CI=1.6,44.3; 
adjusted HR=6.5, 
95%CI=0.9,47.8) 
[34] 
D:A:D 23 468 (median: 1.6 
years) 
126 MIs NS 
Duration of combination ART 
increases the risk of MI (relative 
rate per year of exposure=1.26, 
95%CI=1.12,1.41) 
[28] 
D:A:D 23 468 (mean: 1.54 
years) 
207 CCVE NS 
Duration of combination ART 
increases the risk of CCVE 
(relative rate per year of 
exposure=1.26, 
95%CI=1.14,1.38) 
[27] 
HIV Insight + 
Athena 
18 603 (median: 
3.49 years) 
318 AtDs (92 
MIs) and 2044 
deaths 
Yes 
PI-containing regimen 
associated with increased risk of 
MI (HR=1.19, 95%CI=1.01,1.40) 
[33] 
HIV Insight 7 542 (median = 
mean = 3.5 years) 
127 CCVE Yes 
PI-exposed group had higher 
rates of CCVE (9.8 vs. 
6.5/1000py, p<0.001) and PI 
exposure ≥ 60 days associated 
with higher risk of CCVE 
(adjusted HR=1.71, 
95%CI=1.08,2.74) 
[32] 
ART = antiretroviral therapy; CCVE = cardio- and cerebrovascular events; CHD = cardiovascular heart disease; D:A:D = Data Collection on 
Adverse Events of Anti-HIV Drugs study; HOPS = HIV OutPatient Study; MIs = myocardial infarctions; NNRTI = non-nucleoside reverse 
transcriptase inhibitor; NRTI = nucleoside (nucleotide) reverse transcriptase inhibitors; PI = protease inhibitor; NS = not studied; RTs = 
Randomized trials; RR = risk ratio; HR = hazard ratio; RH = relative hazard; AtD = atherosclerotic disease 
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 The current first-line PI-containing regimen for naïve HIV-infected patients, 
lopinavir boosted with ritonavir [35-37] has been shown to impact on CVD risk 
factors [38]. Even though newer PIs such as atazanavir did not show increase for 
CVD risk when used without ritonavir boost [39], conflicting results have been 
reported when ritonavir is used [40, 41]. Some other newer PIs that would be more 
‘lipid-friendly’, such as tipranavir and darunavir still need more studies to define 
their impact on lipid profile of their chronic use [42]. 
These factors taken together have major public health implications, because 
the profile of HIV-infected patients is changing and that care for these patients 
should include other measures to minimize the risk for these diseases, including 
smoking cessation and weight control. 
In Brazil, where access to HAART has been universal for all patients who 
qualify since 1996, a steep decrease in mortality among HIV/AIDS patients has 
also been documented, but the rates have been fairly stable between 1999 and 
2004 [3, 4]. So far, no data are available about the transition of non-HIV-related 
mortality in these patients. This is public health policy issue, both in terms of 
medication schemes and assessment of patients. 
The objective of this project is to study the profile of non-HIV-related causes 
of death in HIV-infected patients in Brazil, both in the population and individual 
level and its association with ARV use. 
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 2.0 SPECIFIC AIMS 
1. To study changes in causes of death in HIV/AIDS patients in Brazil over 
time in the HAART era at the national level using death certificate data. 
2. To study changes in causes of death in HIV/AIDS patients over time in the 
HAART era in a cohort of HIV+ patients in Rio de Janeiro, using death 
certificate data, combined with a standardized algorithm for ascertainment of 
cause of death. 
o Describe HIV- and non-HIV-related death rates and the proportion 
of non-HIV-related causes of death over time. 
o Search for factors associated with increased non-HIV-related 
causes of death (e.g. CD4 levels, age) 
3. To develop a computerized algorithm to perform linkage between cohort 
databases and other databases that contain relevant information for 
research, that yield high sensitivity and specificity, focusing especially on 
significantly reducing losses to follow-up using death certificate databases in 
Brazil. 
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 3.0 PAPER #1: INCREASE IN NON-AIDS RELATED CONDITIONS AS CAUSES 
OF DEATH AMONG HIV-INFECTED INDIVIDUALS IN THE HAART ERA IN 
BRAZIL 
Published in PLoS ONE on January 30, 2008 – PLoS ONE 2008, 3(1): e1531 
 
Antonio G. Pacheco1,2*, Suely H. Tuboi2,3, José C. Faulhaber3, Lee H. Harrison2, 
Mauro Schechter4 
 
1 Department of Epidemiology and Quantitative Methods in Health, National School 
of Public Health/Scientific Computing Program, FIOCRUZ, Brazil, 2 Infectious 
Diseases Epidemiology Research Unit, Graduate School of Public Health and 
School of Medicine, University of Pittsburgh, PA, USA, 3 Projeto Praça Onze, 
Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, 
Brazil, 4 AIDS Research Laboratory, Hospital Universitario Clementino Fraga Filho, 
Universidade Federal do Rio de Janeiro, Brazil 
 
 10
 3.1 ABSTRACT 
Background: In 1996, Brazil became the first developing country to provide free 
and universal access to HAART. Although a decrease in overall mortality has been 
documented, there are no published data on the impact of HAART on causes of 
death among HIV-infected individuals in Brazil. We assessed temporal trends of 
mortality due to cardiovascular diseases (CVD), diabetes mellitus (DM) and other 
conditions generally not associated with HIV-infection among persons with and 
without HIV infection in Brazil between 1999 and 2004. 
Methodology/Principal Findings: Odds ratios were used to compare causes of 
death in individuals who had HIV/AIDS listed on any field of the death certificate 
with those who did not. Logistic regression models were fitted with generalized 
estimating equations to account for spatial correlation; co-variables were added to 
the models to control for potential confounding. Of 5,856,056 deaths reported in 
Brazil between 1999 and 2004 67,249 (1.15%) had HIV/AIDS listed on the death 
certificate and non-HIV-related conditions were listed on 16.3% in 1999, increasing 
to 24.1% by 2004 (p<0.001). The adjusted average yearly increases were 8% and 
0.8% for CVD (p<0.001), and 12% and 2.8% for DM (p<0.001), for those who had 
and did not have HIV/AIDS listed on the death certificate, respectively. Similar 
results were found for these conditions as underlying causes of death. 
Conclusions/Significance: In Brazil between 1999 and 2004 conditions usually 
considered not to be related to HIV-infection appeared to become more likely 
causes of death over time than reported causes of death among individuals who 
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 had HIV/AIDS listed on the death certificate than in those who did not. This 
observation has important programmatic implications for developing countries that 
are scaling-up access to antiretroviral therapy. 
3.2 INTRODUCTION 
The introduction and widespread use of highly active antiretroviral therapy 
(HAART) has had a profound impact on the HIV/AIDS epidemic, turning a fatal 
disease into a manageable chronic condition. As a consequence, marked 
decreases in AIDS-related morbidity and mortality have been reported in both low- 
and high-income settings [1-4, 43]. However, concerns have been raised about the 
consequences of prolonged exposure to antiretroviral drugs, with some evidence 
for an association between the use of protease inhibitors (PIs) and diabetes 
mellitus (DM) [22] and cardiovascular diseases (CVD) [16, 28]. It has also been 
recently suggested that HIV itself may play a contributing role in the pathogenesis 
of some these conditions [12]. Several recent studies conducted in developed 
countries have documented changes in mortality patterns after the introduction of 
HAART. Although causes of death traditionally associated with HIV/AIDS continue 
to play a predominant role, other conditions, including DM, CVD, cancer, liver and 
renal diseases have been increasingly reported [5-9, 44, 45]. 
In 1996, Brazil became the first developing country to provide free and 
universal access to HAART. In 2004 147,500 patients were receiving HAART 
through the Brazil public health system [46]. In 2005 WHO estimated that ART 
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 coverage in Brazil was in excess of  80% [47]. Although a decrease in overall 
mortality has been documented [3, 4], there are no published data on the impact of 
HAART on causes of death among HIV-infected individuals in Brazil. 
To our knowledge, there are no population-based studies that have 
investigated temporal changes in causes of death among HIV/AIDS patients in 
developing countries after the introduction of HAART. In the present study, we 
assessed temporal trends of overall mortality and of selected conditions usually 
considered not to be related to HIV-infection as causes of death between 1999 and 
2004 in individuals who had and who did not have HIV/AIDS listed on their death 
certificate. 
3.3 RESULTS 
A total of 5,856,056 deaths were reported in Brazil between 1999 and 2004. 
Of these, 67,249 (1.15%) had HIV/AIDS reported in any field of the death 
certificate, corresponding to a stable rate of approximately 6.4 cases/100,000 
inhabitants per year during the study period (p-value for trend=0.67, Figure 3.1A, 
solid circles). According to official figures from the Brazil Ministry of Health [48], the 
death rate associated with HIV/AIDS decreased from 9.3/100,000 in 1996 to 
6.26/100,000 in 1999, and, according to our data, it has remained relatively stable 
until 2004 (Figure 3.1A, open circles).  
In the HIV-group, non-HIV-associated causes of death were listed in 16.3% 
of the death certificates in 1999 and steadily increased to 24.1% in 2004, whereas 
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 in the non-HIV group this ranged from 67.4% to 72.1% in the same period. After 
adjustment for age, gender and state of residence, the average yearly increase of 
non-HIV-associated causes of death in the HIV group was 7.98% 
(95%CI=6.65,9.33; p-value<0.001) and 2.98% for the non-HIV group 
(95%CI=2.22,3.75; p-value<0.001). The slopes of the increase for the two groups 
were significantly different (p-value<0.001). Figure 3.1B shows temporal trends for 
the HIV and for the non-HIV groups, with year as a categorical variable, setting 
1999 as the baseline year. In this model, the OR for having a non-HIV-associated 
condition listed on the death certificate in 2004 compared to 1999 was 1.6 
(95%CI=1.48,1.72; p-value<0.001) for the HIV group, and 1.19 (95%CI=1.14,1.23; 
p-value<0.001) for the non-HIV group and (Table 3.1); the interaction with year as 
a categorical variable was also highly significant (p-value<0.001). 
CVD increased in the HIV group from 4.3% in 1999 to 6.4% in 2004 
(adjusted average increase of 7.79% per year; (95%CI=5.74,9.66; p-value<0.001). 
In the non-HIV group, an increase of 0.80% per year was observed 
(95%CI=0.28,1.33; p-value=0.002), from 36.2% in 1999 to 39.3% in 2004. 
Compared to 1999, the OR for having CVD listed on the death certificate in 2004 
was 1.5 (95%CI=1.34,1.68; p-value<0.001) for the HIV group and 1.07 
(95%CI=1.04,1.10; p-value<0.001) for the non-HIV groups (Table 5.2). Temporal 
trends for both groups are shown in Figure 5.2A; both interactions between year as 
a continuous or a categorical variable were significantly different between the two 
groups (p-value<0.001). 
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 A similar phenomenon was observed for DM, in which an adjusted annual 
increase of 12.3% (95%CI=8.13,16.56;, p-value<0.001), from 0.6% in 1999 to 1.4% 
in 2004 was observed in the HIV group, in contrast with an adjusted increase of 
2.83% per year in the non-HIV group (95%CI=1.95,3.72,, p-value<0.001), from 
6.2% in 1999 to 7.7% in 2004 (Figure 5.2 B, Table 5.3). Compared to 1999, the OR 
for having DM listed on the death certificate in 2004 was 2.16 (95%CI=1.65,2.82; 
p-value<0.001) for the HIV group and 1.2 (95%CI=1.13,1.26; p-value<0.001) for 
the non-HIV group. The increase in the HIV group was again steeper than in the 
non-HIV group, both with year as a continuous or as a categorical variable 
(p<0.001). 
In the analysis of underlying causes of death among HIV-infected patients, 
non-HIV-related conditions, CVD and DM increased significantly from 1999 to 
2004, a result that corroborates our findings when all causes listed on death 
certificates were analyzed (data not shown). 
3.4 DISCUSSION 
The online availability of all death certificates issued in Brazil provided the 
opportunity to compare reported causes of death in 1999, the first year in which 
death certificates contained primary, secondary, and contributing causes of death 
according to ICD-10 codes, with later years among individuals who had HIV/AIDS 
listed on the death certificate.. To our knowledge, this is the first report on temporal 
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 changes in causes of death among HIV/AIDS patients at the population level in a 
developing country in the HAART era.  
The present study suggests that, in Brazil, similar to what has been reported 
from developed countries, mortality patterns among HIV/AIDS patients are 
changing in the HAART era. We found that, in comparison to 1999, there was a 
steady and significantly larger increase in the frequency with which conditions not 
usually associated with HIV/AIDS were listed as causes of death increased for 
individuals who also had HIV listed on the death certificate than in individuals who 
did not, from 16.3% in 1999 to 24.1% in 2004, representing 14,746 deaths in the 
period. In particular, listing of CVD or DM as causes of death represented 3,746 
and 744 deaths, respectively, both appearing to become more likely causes of 
death over time in individuals whose death certificate also included HIV/AIDS than 
in those who did not. Additionally, during the same period there were statistically 
significant increases in these conditions as underlying causes of death among 
individuals who had HIV/AIDS mentioned on their death certificates. 
We speculate that theses changes are not explained by aging of the 
population alone, given that the mean age of death in the non-HIV group increased 
marginally more than the mean age of death in the HIV group (data not shown). 
Thus, certain potentially preventable and/or treatable conditions, such as CVD and 
DM, may have played significant roles in these changes, given that the proportion 
of death certificates in which these conditions are listed increased significantly 
faster in individuals for whom HIV was listed on the death certificate than in those 
for whom it was not listed. 
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 Our results are in agreement with reports from developed countries where 
the sharp decrease in mortality following the introduction of HAART was 
accompanied by significant changes in mortality patterns among HIV-infected 
individuals. In these countries, after a steep decrease in mortality rates following 
the introduction of HAART, mortality rates have been reasonably stable since the 
late 1990’s. For example, in the United States, mortality rates declined abruptly in 
1994/1995, but remained stable from 1998 onwards, at approximately 7 
deaths/100,000 population [49, 50]. In countries where HIV prevalence is well 
defined and thus could be used as the denominator, a steady increase in the 
proportion of deaths attributed to conditions that generally are not attributed to HIV 
infection, such as CVD and DM [5-9, 43], has been reported. We were not able to 
perform similar analyses, given the absence of reliable estimates of HIV 
prevalence in most regions of Brazil. 
Our results are also in agreement with what has been reported in 
population-based studies conducted in developed countries. For example, 
combining information on HIV/AIDS surveillance in New York City with vital 
statistics data, Sackoff et al. [6] showed an increase in the proportion of non-
HIV/AIDS-related causes of death from 19.8% to 26.3% between 1999 and 2004, 
with CVD ranking second overall and DM reaching 4.4% of all non-HIV-related 
causes of death in women. In another population-based study in the U.S., Selik et 
al., using a similar approach to ours but limiting the analysis only to those who had 
HIV/AIDS listed on the death certificate, showed that CVD increased from 4% to 
7.7% from 1987 to 1999, with a steeper increase between 1996 and 1999 [9]. 
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 Similar trends have also been documented in cohort studies. In the CASCADE 
Collaboration, CVD and DM as a group increased from 1.3% in the pre-HAART era 
to 4.3% in post-HAART era [7]. In the HIV Outpatient Study, Palella et al. showed 
that non-HIV/AIDS-related causes of death increased from 13.1% to 42.5% 
between 1996 and 2004 in 12 clinics in the United States, with CVD being leading 
cause of death in this group in 2004 [8]. Crum et al., studying an HIV cohort of U.S. 
military beneficiaries, also showed increases in cardiac disease (from 8% to 22%) 
and DM (from 0% to 3%) being listed on death certificates in the pre- and post-
HAART era, respectively [5]. In a simulation study, Braithwaite et al predicted that 
HIV-infected patients will be increasingly dying of co-morbidities not related to HIV 
infection. For example, they predicted that a 30 years old patient with a high CD4 
count and low viral load would have a 45% chance of dying from non-HIV related 
causes, and that up to 35% of these would be CVD [44]. Given the absence of 
reliable estimates of HIV prevalence in most regions of Brazil, we were not able to 
provide estimates of actual trends among HIV-infected individuals. Nonetheless, 
we believe that our findings are likely to reflect a changing mortality pattern among 
HIV/AIDS patients in Brazil that could be associated with widespread availability of 
HAART [51], a pattern similar to that in developed countries. It should be noted that 
it is estimated that over 80% of HIV infected patients who, according to 
international guidelines, were in need of treatment in Brazil were on antiretroviral 
therapy during the study period[47]. 
A major strength of our study is that we analyzed all available data from all 
death certificates issued in a large developing country over a six year period, which 
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 allowed us to investigate temporal trends in causes of death by comparing 
individuals who had HIV/AIDS listed in their death certificates to those who did not. 
Furthermore, the use of any mention of conditions on the death certificate as 
opposed to only the underlying cause of death allowed us to overcome one of the 
limitations of the current ICD system, which does not cover some diseases 
associated with HIV [45], as well as to capture the contributing effect of other 
conditions. Since HIV-infected individuals now live longer [5, 8] and thus have 
longer periods of time at risk for chronic conditions associated with aging, an 
increase in the frequency of CVD and DM is to be expected. There are also data 
that indicate an association between certain antiretroviral drugs as well as time on 
therapy and risk for CVD [28, 52]. Additionally, recent data suggest that HIV 
replication may be associated with increased levels of pro-inflammatory markers 
which, in turn, are involved in the pathogenesis of CVD [12]. 
Our study has several limitations. Most importantly, we only analyzed data 
from death certificates, which may lack sensitivity and specificity for medical 
conditions [53-55]. Nonetheless, by using an approach akin to MOR [56], a 
strategy that is commonly utilized in studies that investigate occupational hazards, 
we were able to estimate relative risks by comparing individuals who had HIV/AIDS 
cited in their death certificates to those who did not. The main difference from the 
classical use of MOR was that the focus of our analysis was not to compare risks 
between groups, but to compare temporal trends among them. This approach was 
chosen due to the lack of reliable estimates of the prevalence of HIV infection in 
Brazil, particularly age and gender distribution. Additionally, as is the case for all 
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 population-based studies, we cannot exclude the influence of unknown 
confounders that may have contributed to increased reports of non-HIV associated 
causes of death or to changes over time in the frequency in which HIV/AIDS is 
listed on death certificates. The latter, if present, probably did not play a significant 
role, given the stable rate of HIV/AIDS being listed on death certificates, which in 
turn is in agreement with reports that indicate that HIV-related mortality has 
remained stable since 1999 [3, 4]. Information on the proportion of those who had 
HIV/AIDS listed on their death certificate and who were or had been on 
antiretroviral therapy is not available, as well as other important confounders such 
as smoking and other risk factors for CVD, and thus could not be assessed in our 
analyses. However, since HAART is freely and universally available for all those 
who qualify for treatment according to treatment guidelines that are virtually 
identical to those used in developed countries [36, 37], it is likely that the vast 
majority of those who had HIV/AIDS listed on the death certificate were or had 
been on HAART. 
In conclusion, this is the first study to examine changes in mortality patterns 
among HIV-infected individuals in Brazil after the introduction of HAART. Of 
particular importance is the finding that conditions that potentially may be 
prevented and/or treated, such as CVD and DM, have appeared to become more 
likely causes of death over time among HIV-infected individuals than in the general 
population. The immediate implication of this finding is that the clinical 
management of persons living with HIV/AIDS should include prevention, diagnosis, 
and treatment of chronic conditions, such as CVD and DM. At the program level, 
 20
 the Brazilian network of treatment facilities will need to increase its capacity to 
diagnose and manage co-morbidities that can influence outcome. This, in turn, 
reinforces the need to integrate HIV/AIDS programs with other public health 
programs, in order to establish a healthcare infrastructure that is capable to take 
the necessary measures to prevent, diagnose, and treat these conditions [57]. 
Finally, for other developing countries that are just starting to scale-up their 
programs, lessons learned from the Brazilian experience might help to prepare in 
advance to changes in morbidity and mortality patterns that will likely occur once 
HAART becomes widely available. 
3.5 MATERIALS AND METHODS 
In Brazil the death certificate is a standardized form that is filled out by a 
physician. Until 1998, death certificates only included the underlying cause of 
death. Since 1999, death certificates, besides containing demographic information, 
include primary, secondary, and contributing causes of death according to the 
International Classification of Diseases 10th revision (ICD-10) codes [53]. All death 
certificates issued in Brazil are entered in datasets without personal identifiers and 
are available online at 
http://tabnet.datasus.gov.br/tabdata/sim/dados/cid10_indice.htm. This national 
database is known as the Brazilian Mortality Information System (Sistema de 
Informações sobre Mortalidade [SIM]).  
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 In this study, we investigated trends for all causes of death mentioned on 
death certificates in Brazil between 1999 and 2004. During the study period Brazil 
had a population of approximately 173 million people [58]. We compared temporal 
trends in causes of death among individuals who had HIV/AIDS listed in any field 
of the death certificate (ICD-10 codes B20-B24, Z21), referred to as the HIV group, 
with those who did not have HIV/AIDS reported on the death certificate (the non-
HIV group) using an approach akin to the mortality odds-ratio (MOR) focusing on 
temporal trends, not on the risk of dying with the studied causes, which would be 
the classical use of MOR [56]. 
We conducted three separate analyses, in which the outcomes were defined 
as the presence or absence in any field of the death certificate of: [I] non-HIV-
associated causes, defined as non-HIV-related neoplasms (C00-C80, except C46 
– Kaposi’s sarcoma), DM (E10-E14), CVD (I00-I99), except cardiac arrest (I46), 
digestive diseases (K00-K93), genital-urinary diseases, (N00-N99) and external 
causes (S00-Y98); [II] CVD (I00-I99), except cardiac arrest (I46); and [III] DM (E10-
E14). Additionally, we also examined these outcomes as the underlying cause of 
death, as defined by the World Health Organization (WHO), in individuals who had 
HIV/AIDS mentioned on their death certificates [59]. The underlying cause of 
death, which consists of only one cause per death certificate, is coded by local 
health departments based on standard rules [60], and is the official figure reported 
by the Brazil Ministry of Health to WHO for mortality statistics. 
Logistic regression models were fitted and co-variables were added to the 
models to control for possible confounding, including age group (<15; 15-29; 30-39; 
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40-49; 50-59; >=60 years); gender; year of death; and state of residence. Age 
groups were used to avoid low numbers in some regions of the curves. 
Generalized estimating equations (GEE) were used to fit the logistic models and to 
account for spatial correlation structures in the data (i.e. using state of residence as 
clusters), which were assumed to be interchangeable for this analysis.  
Year of death was treated either as a continuous (linear) or categorical 
variable in the models. In the former case, linear trends are reported as 
percentages per year, while in the latter, odds ratios are used to compare yearly 
changes to the baseline year of 1999. Differences in slopes in temporal trends 
were tested by an interaction term between HIV status and year. Reference groups 
were <15 years for age, female for gender, and São Paulo State for state of 
residence. 
All analyses were performed in R for Windows v. 2.4.1 [61], using the 
package ‘geepack’ for GEE estimation [62]. 
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Figure 3.1. Death Rates and non-HIV-related causes of death. A – Death rates per 100 000 inhabitants of individuals that had HIV/AIDS listed on the death 
certificate, 1999-2004 (p-value for trend = 0.67, solid circles) and AIDS mortality as an underlying disease from 1996 to 2004 (open circles). B – Odds 
ratios and 95% confidence intervals of non-HIV-related causes of death listed on the death certificate in individuals who had and who did not have HIV 
listed on the death certificate. Slopes of trends are significantly different between the two groups (p-value<0.001) 
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Figure 3.2. CVD and DM in HIV-infected/AIDS patients. Odds ratios and 95% confidence intervals comparing the chance of having the disease listed on 
the death certificate over time, compared with 1999. A – CVD; B – DM. Slopes for trends are significantly different between groups for CVD (p-
value<0.001) and DM (p-value<0.001) 
 3.7 Tables 
 
Table 3.1. Description and odds ratios of having a non-HIV related condition* in any field of the death certificate stratified by reported HIV status** 
non-HIV (N=5788807) HIV (N=67249) 
Variable 
n (%) OR (95% CI) P-value n (%) OR (95% CI) P-value 
Outcome 
Non-HIV-
related 
4059422 (70.12%) - - 14746 (21.93%) - - 
1999 625767 (67.43%) Reference  1774 (16.6%) Reference  
2000 649305 (69.39%) 1.07 (1.05-1.1) 2317 (21.09%) 1.33 (1.23-1.44) 
2001 665383 (70.02%) 1.1 (1.07-1.12) 2494 (22.24%) 1.43 (1.31-1.56) 
2002 685628 (70.58%) 1.11 (1.08-1.15) 2628 (23.11%) 1.5 (1.38-1.62) 
2003 702692 (70.93%) 1.13 (1.09-1.17) 2737 (23.56%) 1.52 (1.4-1.64) 
Year of death
2004 730647 (72.15%) 1.19 (1.14-1.23) 
<0.001 
2796 (24.58%) 1.6 (1.48-1.72) 
<0.001 
Female 1659581 (68.4%) Reference  4369 (20.98%) Reference  
Gender 
Male 2399841 (71.37%) 1.08 (1-1.17) 0.015 10377 (22.35%) 1.06 (1.01-1.11) 0.03 
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 Table 3.1. Continued: 
 
<15 97573 (19.46%) Reference  232 (14.14%) Reference  
15-29 352801 (83.44%) 20.44 (16.83-24.81) 2057 (15.9%) 1.15 (1-1.33) 
30-39 262805 (76.66%) 12.99 (11.2-15.07) 5387 (20.39%) 1.5 (1.31-1.71) 
40-49 390424 (76.88%) 12.79 (11.14-14.69) 4186 (24.59%) 1.89 (1.65-2.16) 
50-59 535089 (78.34%) 13.85 (12.1-15.86) 1881 (29.81%) 2.47 (2.14-2.86) 
60+ 2400943 (72.69%) 10.39 (9.07-11.9) 974 (35.63%) 3.25 (2.81-3.76) 
Age group 
Unknown 19787 (71.11%) 9.29 (7.93-10.88) 
<0.001 
29 (15.85%) 1.17 (0.76-1.8) 
<0.001 
*non-HIV-related neoplasms (C00-C80, except C46 – Kaposi’s sarcoma), DM (E10-E14), CVD (I00-I99), except cardiac arrest (I46), digestive diseases (K00-K93), genital-urinary 
diseases, (N00-N99) and external causes (S00-Y98) 
**Adjusted for state of residency 
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 Table 3.2. Description and odds ratios of having CVD* in any field of the death certificate stratified by reported HIV status** 
non-HIV (N=5788807) HIV (N=67249) 
Variable 
n (%) OR (95% CI) P-value n (%) OR (95% CI) P-value 
Outcome CVD 2196228 (37.94%) - - 3746 (5.57%) - - 
1999 341452 (36.8%) Reference  491 (4.59%) Reference  
2000 360784 (38.56%) 1.07 (1.05-1.09) 579 (5.27%) 1.14 (1-1.3) 
2001 368185 (38.75%) 1.06 (1.04-1.09) 647 (5.77%) 1.25 (1.1-1.43) 
2002 375371 (38.64%) 1.05 (1.02-1.07) 721 (6.34%) 1.38 (1.22-1.57) 
2003 386117 (38.97%) 1.05 (1.02-1.07) 750 (6.46%) 1.39 (1.23-1.57) 
Year of 
death 
2004 404072 (39.9%) 1.07 (1.04-1.1) 
<0.001 
800 (7.03%) 1.5 (1.34-1.68) 
<0.001 
Female 1067296 (43.99%) Reference  1241 (5.96%) Reference  
Gender 
Male 1168685 (34.76%) 0.79 (0.75-0.82) <0.01 2747 (5.92%) 0.98 (0.91-1.05) 0.96 
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 Table 3.2. Continued: 
 
<15 23306 (4.65%) Reference  101 (6.15%) Reference  
15-29 33154 (7.84%) 1.75 (1.43-2.14) 480 (3.71%) 0.59 (0.47-0.75) 
30-39 62250 (18.16%) 4.46 (4.01-4.97) 1331 (5.04%) 0.79 (0.62-0.99) 
40-49 162441 (31.99%) 9.22 (8.54-9.95) 1103 (6.48%) 1.01 (0.8-1.28) 
50-59 289154 (42.33%) 14.33 (13.34-15.39) 590 (9.35%) 1.51 (1.18-1.93) 
60+ 1661862 (50.31%) 19.56 (18.18-21.05) 379 (13.86%) 2.37 (1.85-3.04) 
Age group 
Unknown 3814 (13.71%) 3.53 (2.48-5.02) 
<0.001 
4 (2.19%) 0.35 (0.11-1.16) 
<0.001 
*CVD: ICD10 I00-I99, except cardiac arrest (I46) 
**Adjusted for state of residency 
 30
 Table 3.3. Description and odds ratios of having DM* in any field of the death certificate stratified by reported HIV status**  
non-HIV (N=5788807) HIV (N=67249) 
Variable 
n (%) OR (95% CI) P-value n (%) OR (95% CI) P-value 
Outcome DM 411862 (7.11%)   744 (1.11%) - - 
1999 57312 (6.18%) Reference  63 (0.59%) Reference  
2000 65525 (7%) 1.12 (1.08-1.16) 109 (0.99%) 1.62 (1.21-2.15) 
2001 66886 (7.04%) 1.12 (1.08-1.16) 130 (1.16%) 1.87 (1.39-2.52) 
2002 71025 (7.31%) 1.15 (1.1-1.2) 117 (1.03%) 1.63 (1.23-2.17) 
2003 72933 (7.36%) 1.15 (1.1-1.2) 161 (1.39%) 2.13 (1.63-2.77) 
Year of 
death 
2004 78181 (7.72%) 1.2 (1.13-1.26) 
<0.001 
164 (1.44%) 2.16 (1.65-2.82) 
<0.001 
Female 235268 (9.7%) Reference  240 (1.15%) Reference  
Gender 
Male 176594 (5.25%) 0.59 (0.55-0.64) <0.01 504 (1.09%) 0.9 (0.77-1.04) 0.19 
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Table 3.3. Continued: 
 
<15 617 (0.12%) Reference  0 (0%) Reference  
15-29 3309 (0.78%) Reference  42 (0.32%) Reference  
30-39 6811 (1.99%) 4.86 (3.96-5.95) 171 (0.65%) 2.15 (1.53-3.03) 
40-49 22329 (4.4%) 10.59 (8.74-12.82) 244 (1.43%) 4.68 (3.37-6.49) 
50-59 57967 (8.49%) 20.94 (17.32-25.32) 163 (2.58%) 8.58 (6.15-11.97) 
60+ 320444 (9.7%) 23.07 (19.04-27.96) 122 (4.46%) 15.24 (10.96-21.19) 
Age group 
Unknown 385 (1.38%) 3.89 (2.06-7.33) 
<0.001 
2 (1.09%) 4 (1-16.09) 
<0.001 
*DM: ICD10 E10-E14, except cardiac arrest (I46) 
**Adjusted for state of residency 
 4.0 PAPER # 2 - TEMPORAL CHANGES IN CAUSES OF DEATH AMONG 
HIV-INFECTED PATIENTS IN THE HAART ERA IN BRAZIL 
Manuscript under preparation 
4.1 ABSTRACT 
Objective: To assess temporal trends of mortality due to non-AIDS-related 
conditions in a cohort of HIV infected individuals in Rio de Janeiro, Brazil 
between 1997 and 2006. 
Design: Retrospective cohort study. 
Methods: Death rates were analyzed in two-year periods using Poisson models 
and survival models accounting for competing risks were used to assess 
association of co-variables. A standardized algorithm was used to ascertain 
causes of death. 
Results: Of the 1,538 eligible patients, 226 (14.7%) died during the study 
period. Overall, 98 (43.4%) were classified as non-AIDS-related causes. 
Opportunistic infections were the leading causes of death (37.6%). AIDS-related 
death rates declined significantly over time (p<0.01). In the most recent period 
(2005-2006) the rate of non-AIDS related causes of deaths was higher than that 
of AIDS-related causes of death. CVD increased significantly over time 
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 (p=0.04). There was a 46% increase in risk per 10 years of baseline age for 
AIDS-related causes of death, with a significant and negative interaction over 
time (p=0.02). 
Conclusions: Our results indicate that in the HAART era there has been a 
significant change in causes of death among HIV-infected patients in Rio de 
Janeiro, Brazil. The major driving force behind this change appears to be longer 
survival due to the significant decrease in deaths due to AIDS-related causes. 
As access to HAART improves and HIV becomes a chronic condition, 
integration with other public programs, such as smoking cessation and control 
of hypertension will become critically important for the long term success of 
HIV/AIDS programs in developing countries. 
 
Key words: HIV, AIDS, Brazil, causes of death 
4.2 INTRODUCTION 
In the past decade, the introduction and widespread use of highly active 
antiretroviral therapy (HAART) has led to marked decreases in mortality and 
morbidity in low- and high-income countries [1-4], turning a deadly disease into 
a manageable chronic condition.  
In developed countries, population-based and cohort studies have 
demonstrated that, although HIV/AIDS-related conditions remain the most 
frequent causes of death, other conditions, including diabetes mellitus (DM), 
cardiovascular diseases (CVDs), cancer, liver and renal diseases, have become 
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 increasingly frequent in HIV-infected individuals [5-9]. In fact, in some 
populations, such as patients with CD4+ counts greater than 200 cells/mm3, 
non-HIV-related causes of death are now more frequent than HIV-related ones 
[10].  
Due to the increased survival, the HIV-infected population tends to 
become older [63], a factor that in itself may contribute to the increased 
frequency of non-HIV/AIDS-related causes of death. An association between 
certain HAART regimens, particularly those containing protease inhibitors or 
abacavir, and risk of CVD and conditions such as the metabolic syndrome has 
been reported [11, 24-34]. A possible contributing role of uncontrolled HIV 
replication on the risk of non-HIV-related deaths has also been suggested [12]. 
In Brazil, where free access to HAART has been universal for all patients 
who qualify for treatment under locally developed guidelines since 1996, 
although mortality rate among HIV-infected patients decreased sharply after the 
introduction of HAART, it has remained stable since 1999 [3, 4]. Recently, 
based on data from the national databases of death certificates, we reported a 
significant increase between 1999 and 2004 in non-HIV-related conditions, 
including CVD and DM, as causes of death, [64]. 
In this study, we describe changes in temporal trends of causes of death 
in a cohort of HIV-infected patients in Rio de Janeiro, Brazil.  
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 4.3 METHODS 
4.3.1 Data sources 
All patients included in the study were followed in the Rio de Janeiro 
cohort. The Rio de Janeiro cohort is a participating site of  the ART-LINC 
collaboration (http://www.ispm.ch/artlinc.html) [1, 65] and of CCASAnet 
(http://ccasanet.vanderbilt.edu) of the IeDEA network (http://www.iedea-hiv.org). 
Patients who entered the cohort between 1997 and 2006, were aged 16 years 
or older, and had at least one follow-up visit were eligible for the present study. 
Laboratory data, including CD4 counts and viral load, are electronically 
transferred from the hospital database. Clinical data are abstracted from 
hospital charts immediately after consultations by trained data abstractors who 
fill out specially designed forms that contain all relevant fields and variables. 
Vital status was ascertained either by abstracting information from 
medical charts or by linkage with the Rio de Janeiro Mortality Database, using a 
previously validated algorithm [66]. Information from death certificates obtained 
through the linkage algorithm, which included primary and contributing causes 
of death, was used in the ascertainment of causes of death as described below.  
4.3.2 Ascertainment of causes of death 
Causes of death were determined using the CoDe (Coding Causes of 
Death in HIV) protocol [67]. Briefly, extensive data were collected from all 
available sources, including death certificates, medical records, autopsy reports, 
and information obtained from family members by a trained physician or health 
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 care provider. Two independent reviewers attributed causes of death based on 
the completed CoDE forms. If the attributed cause of death was the same for 
both reviewers, it was considered to have been established. If there was 
disagreement between the two reviewers, or both had coded the cause of death 
as unknown or unclassifiable, the case was referred to a third reviewer for final 
classification.  
Causes of death were classified as AIDS-related or non-AIDS-related 
based on the presence or absence of  an AIDS-defining condition, according to 
the Centers for Disease Control and Prevention Classification [68], as a primary 
or a contributing cause of death. All deaths with unknown primary and 
contributing causes for which at least one CD4 cell count was available within 6 
months prior to the date of death were classified as AIDS-related if CD4 counts 
were < 200 cells/mm3 and as non-AIDS-related if ≥ 200 cells/mm3. Deaths that 
did not meet any of the above criteria were classified as of unknown cause. 
Specific underlying causes of death were further categorized according 
to whether or not they were AIDS-related as follows: a) AIDS-related (according 
to CDC definitions): opportunistic diseases; cancer; both cancer and 
opportunistic diseases; and undefined disease(s); b) non-AIDS–related: 
hepatitis/liver-related; infectious diseases; non-AIDS-related cancer; external 
causes; CVD; other diseases; and unknown.  
4.3.3 Statistical analysis 
Descriptive statistics are presented for the variables considered 
comparing living patients with deceased patients due to AIDS-related, non-
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 AIDS-related, and unknown causes of death. For continuous variables, non-
parametric Kruskal-Wallis tests were used followed by pairwise Wilcoxon tests 
with Holm’s multiple comparisons corrections; for discrete variables, overall 
Fisher exact tests were performed. 
Two-year rates of AIDS- and non-AIDS-related causes of death and CVD 
per 100 person-years (py) were calculated and compared over time to detect 
temporal changes. Poisson regression models were employed and correlation 
and overdispersion were handled by using quasi-Poisson corrections for 
variance estimation [69]. 
Survival analysis regression models were performed in the context of 
competing risks [70, 71]. This approach makes it possible to account for 
differences between non-informational censoring due to study termination or 
independent losses to follow-up and informational censoring, when “losses” are 
due to death by causes other than the one(s) studied, allowing for correct 
modeling of the main outcome and competing risk(s) [71-73]. Classically, event-
specific hazards are modeled separately for the event of interest and the 
competing risk, which tends to overestimate the cumulative mortality, since it 
considers that the competing event does not exist. Another problem with this 
approach is that the assumption of proportionality across covariates strata will 
usually be violated and inferences could be biased [72]. A new approach 
proposed by Fine and Gray [74, 75] allows the estimation of the subdistribution 
hazards for each event, which takes into account the competing risks, allowing 
for unbiased estimation of the cumulative incidence functions (CIFs) and is 
implemented in the ‘cmprsk’ library [76] in the R software. Adjusted hazard 
ratios (aHR) of the subdistributions are reported for the models. 
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 Variables analyzed included gender, age at start of observation, age at 
the end of observation or death, transmission group [heterosexual, men who 
have sex with men (MSM), intravenous drug users (IDU), other and unknown], 
baseline CD4 counts, use of HAART and use of PI-containing regimens. 
All analyses were performed in R for Windows [61]. 
Institutional Review Board approval was obtained both from the Hospital 
Universitário Clementino Fraga Filho, where the cohort is being followed, and 
the University of Pittsburgh. 
4.4 RESULTS 
Of the 1,633 potentially eligible patients, 95 (5.8%) females were 
excluded from the analysis because they were followed only during pregnancy. 
Of the 1,538 eligible patients, who contributed 7,037 person-years of follow-up, 
226 (14.7%) were known to have died during the study period. Of those known 
to have died, 82 (36.3%) were identified only through using the linkage 
algorithm with the Rio de Janeiro Mortality database. The mortality rate was 
3.2/100 person-years, which is over 50% higher than the rate that would be 
obtained had these 82 deaths not been identified (2.0/100 py; difference = 1.2; 
95%CI = 0.9,1.4; p < 0.01). The median follow-up time was 4.61 years (IQR = 
5.63 years) and the loss to follow-up rate, defined as absence of any 
information for more than one year, was 2.4/100 person-years.  
Overall, 111 (49.1%) deaths were considered to be due to AIDS-related 
causes, whereas 98 deaths (43.4%) were classified as due to non-AIDS-related 
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 causes. Patients who died from non-AIDS related deaths contributed more 
follow-up time than patients who died from AIDS-related causes (median time = 
3.39 py vs. 1.45 py, respectively, p < 0.01) (Table 4.1). Rates of death from 
AIDS-related causes (1.58/100 py) and from non-AIDS-related causes 
(1.39/100 py) were not statistically different (p = 0.37).  
Baseline CD4 cell counts were significantly lower for deceased patients 
compared to patients alive at the end of the follow-up period (p < 0.01 for both 
AIDS- and for non-AIDS-related causes of death). Nonetheless, after multiple 
comparisons adjustment, the difference in baseline CD4 counts between 
patients who died from AIDS- and from non-AIDS-related causes of death was 
not statistically significant (148 vs. 95 cells/mm3, respectively, p = 1). 
The distribution of causes of death is shown in Table 4.2. Opportunistic 
infections were the leading causes of death (37.6%). Among non-AIDS-related 
causes, infectious diseases were also the most frequent causes (8.4%), 
followed by external causes (4.9%) and CVD (4.0%). 
Death rates remained fairly stable during the study period (p = 0.57), 
despite a significant decrease when the initial period (1997-1998) was 
compared to the final period (2005-2006) of observation (p < 0.01) (Table 4.3 
and Figure 4.1A). AIDS-related causes of death declined significantly over time 
(p < 0.01), while non-AIDS-related causes of death increased over time, 
although not significantly (p = 0.46). Nonetheless, in the most recent period 
(2005-2006) the rate of non-AIDS related causes of deaths was higher than that 
of AIDS-related causes of death (1.59/100 py and 1.24/100 py, respectively). 
Despite the relatively small number of cases, CVD as a cause of death 
increased significantly over time (p = 0.04). 
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 The cumulative incidence functions for the hazards subdistributions for 
AIDS-related, non-AIDS-related and unknown causes of death in a competing 
risks framework is shown in Figure 4.2. At the beginning of the observation 
period, AIDS-related causes of death had a higher cumulative incidence than 
non-AIDS related causes of death, but 7 years later the cumulative incidence of 
non-AIDS related causes of became higher than that of AIDS-related causes of 
death. In Table 4.4 we present models for the hazard subdistributions for AIDS- 
and non-AIDS related causes of death, treating age at the start of the 
observation period as a time-dependent variable and adjusting for baseline CD4 
cell count, gender, and risk factor for HIV infection. The models indicate that 
baseline CD4 cell count is strongly associated with protection for both AIDS- 
and non-AIDS-related causes of death (10% and 13% per 50 cells increase, 
respectively) and that intravenous drug use is a significant risk factor for non-
AIDS-related causes of death (aHR = 4.96; 95% CI: 2.34,10.52; p < 0.01), but 
not for AIDS-related causes of death. Although baseline age was not associated 
with non-AIDS-related causes of death, there was a 46% increase in risk per 10 
years of baseline age for AIDS-related causes of death, with a significant and 
negative interaction over time (p = 0.02), indicating that risk decreased 
significantly over time. 
HAART use during observation time and PI use were not significantly 
associated with non-AIDS-related causes of death (HR = 0.7; 95%CI: 0.44,1.09; 
p = 0.11 and HR = 1.23; 95%CI: 0.82,1.86; p = 0.32, respectively). 
Using more restrictive criteria that are also part of the CoDe algorithm, 
that classify deaths according to CD4 cell counts closer to death and if the 
death was sudden or non-sudden, deaths were further classified as due to 
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 immunodeficiency-related causes or to non-immunodeficiency related causes. 
Death rates due to causes not related to immunodeficiency significantly 
increased over time (0.54 vs. 0.84 deaths per 100 py, in 1997-1998 and 2005-
2006, respectively; p < 0.01), even though death rates due to causes related to 
immunodeficiency were consistently and significantly higher throughout the 
study period (data not shown). 
4.5 DISCUSSION 
Our results show that overall mortality rates in a large cohort of HIV-
infected patients in Rio de Janeiro, Brazil, remained fairly stable between 1999 
and 2006. This is in agreement with other studies that showed that in Brazil, 
although mortality rates declined sharply after HAART became widely available, 
they have remained stable since 1999 [4, 64]. In our study, when AIDS- and 
non-AIDS-related causes of death are examined separately, a decrease in 
AIDS-related causes of death and an increase in non-AIDS-related causes of 
death were observed. When more restrictive criteria were used to classify 
causes of death, non-immunodeficiency related causes of death increased 
significantly over time. Even though the temporal trend for non-AIDS-related 
causes of death did not reach statistical significance, in the most recent study 
period (2005-2006) non-AIDS-related causes of death became more frequent 
than AIDS-related causes of death. Despite the small number of cases, during 
the study period there was a significant increase of CVD as a cause of death (p 
= 0.04). Thus, the distribution and temporal trends for specific groups of causes 
of death we encountered are in agreement with reports from developed 
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 countries, in which although opportunistic infections remain the main cause of 
death, non-AIDS-related causes of death are becoming increasingly common 
[7, 10]. 
In a regression model for the hazards subdistribution adjusted for 
possible confounders, although baseline age was significantly associated with 
risk for AIDS-related causes of death, the risk significantly decreased over time. 
On the other hand, baseline age had no significant effect on the risk for non-
AIDS-related causes of death. These results indicate that, as patients age 
because of longer survival times, they become at higher risk of dying from a 
non-AIDS-related condition. These findings are in accordance with the recent 
description of HIV cohorts tending to get older [63], as is the case in our cohort, 
where the median age significantly increased from 33.25 years in 1997 to 39.0 
years in 2006 (p < 0.01). 
Our results are in agreement with several reports in the literature that 
have documented changes in causes of death among HIV-infected patients in 
the HAART era. Using combined information on HIV/AIDS surveillance with vital 
statistics data from New York City, Sackoff et al. [6] showed an increase in the 
proportion of non-HIV/AIDS-related causes of death from 19.8% to 26.3% 
between 1999 and 2004, with CVD ranking second among them. Selik et al. 
showed that for patients who had HIV/AIDS mentioned on the death certificate 
in the United States, CVD increased from 4% to 7.7% from 1987 to 1999, with a 
steeper increase between 1996 and 1999. In the CASCADE Collaboration, CVD 
and DM as a group increased from 1.3% in the pre-HAART era to 4.3% in post-
HAART era [7]. In the HIV Outpatient Study, Palella et al. [8] showed that non- 
AIDS-related causes of death increased from 13.1% to 42.5% between 1996 
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 and 2004, with CVD being the leading cause of death in this group in 2004. 
Crum et al., studying a cohort of U.S. military beneficiaries, also showed 
increases in cardiac disease (from 8% to 22%) and DM (from 0% to 3%) being 
listed on the death certificates in the pre- and post-HAART era, respectively [5]. 
We have recently shown that in Brazil between 1999 and 2004 the proportion of 
non-AIDS-related causes of death reported on death certificates of patients that 
had HIV/AIDS as one of the causes of death increased significantly, as did CVD 
[64]. 
Among the main strengths of our study was the use of a database 
linkage algorithm that allowed us to determine the vital status of patients who 
otherwise would be considered to be lost to follow-up, which increased the 
death rate by 57% and kept the loss to follow-up rate at 2.4/100 person-years. 
Another strength of our study was the use of the CoDe algorithm [67], which 
allowed for a standardized classification of causes of death, which would not be 
possible if only data abstracted from death certificates or medical charts were 
used. 
The main limitation of our study was the relatively small number of 
deaths (n = 226), which made some of the models we used underpowered for 
associations. Another limitation was the retrospective nature of the study, which 
did not allow us to investigate potentially important variables, such as 
adherence to treatment, smoking status, hepatitis co-infection, and lipid and 
cholesterol blood levels.  
In conclusion, our results indicate that in the HAART era there has been 
a significant change in causes of death among HIV-infected patients in Rio de 
Janeiro, Brazil. Although overall death rates remained stable after 1999, deaths 
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from AIDS-related causes decreased, while deaths from non-AIDS-related 
causes increased to the point that the latter became more common than the 
former. The major driving force behind this change appears to be longer 
survival due to the significant decrease in deaths due to AIDS-related causes. 
Our findings have major programmatic implications for developing countries. As 
access to HAART improves and HIV becomes a chronic condition, integration 
with other public programs, such as smoking cessation and control of 
hypertension will become critically important for the long term success of 
HIV/AIDS programs in developing .countries. 
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Figure 4.1. Temporal trends of deaths in the cohort. A – Overall deaths; B – AIDS and 
Non-AIDS-related causes of death 
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Figure 4.2. Cumulative incidence functions (CIFs) of the subdistributions of deaths 
associated with AIDS-, non-AIDS-related and unknown causes in a competing risks 
framework. 
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 4.7 Tables 
Table 4.1. General descriptions of variables analyzed 
  Alive 
AIDS-related1 
Death 
Non-AIDS-
related2 
Death 
Overall p-
value3 Unknown Total 
N 1312 111 98  17 1538 
Median 4.99 1.45# 3.39#§ <0.01 3.52 4.61 
IQR 5.8 3.1 4.62  3.52 5.63 
Total 6360.36 250.28 363.14  63.76 7037.54 
PYs 
% 85.31 7.22 6.37 - 1.11 100 
Death rates per 100 
person-years - 1.58 1.39 0.37 0.24 3.21 
N 1312 111 98  17 1538 
Median 33.02 35.07 36.37 0.02 35.85 33.62 
Age at  
start 
IQR 14.53 13.29 18.02  15.28 14.81 
N 1312 111 98  17 1538 
Median 38.68 38.02 41.17 0.47 37.44 38.7 Age in the end 
IQR 14.97 11.98 15.18  13.95 14.94 
Female 673 46 44 Ref 9 772 
% 51.3 41.44 44.9  52.94 50.2 
Male 639 65 54 0.16 8 766 
Gender 
% 48.7 58.56 55.1  47.06 49.8 
Heterosexual 661 45 48 Ref 7 761 
% 50.38 40.54 48.98  41.18 49.48 
MSM 222 16 6 0.04 5 249 
% 16.92 14.41 6.12  29.41 16.19 
IDU 40 5 6 0.13 1 52 
% 1.14 2.7 9.18  0 1.76 
Other 40 5 6 0.13 1 52 
% 3.05 4.5 6.12  5.88 3.38 
Unknown 374 42 29 0.16 4 449 
Group 
% 28.51 37.84 29.59  23.53 29.19 
N4 1248 106 96  15 1465 
Median 268.38 95.36# 148.36# <0.01 182 250 Baseline CD4 
IQR 337.05 272.36 299.6  277.71 338.25 
No 314 34 26 Ref 6 380 
% 23.93 30.63 26.53  35.29 24.71 HAART ever 
Yes 998 77 72 0.26 11 1158 
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 Table 4.1. Continued: 
 
 % 76.07 69.37 73.47  64.71 75.29 
No 433 36 31 Ref 6 506 
% 33 32.43 31.63  35.29 32.9 
Yes 879 75 67 0.98 11 1032 
HAART 
during 
observaion 
% 67 67.57 68.37  64.71 67.1 
No 662 57 36 Ref 9 764 
% 50.46 51.35 36.73  52.94 49.67 
Yes 650 54 62 0.07 8 774 
PI ever 
% 49.54 48.65 63.27  47.06 50.33 
1 Pair-wise p-value < 0.05 comparing with alive patients: # 
2 Pair-wise p-value < 0.05 comparing with alive patients: #; comparing with the competing 
cause: § 
3 Overall p-values for Kruskal-Wallis test in continuous variables and Fisher exact test for 
discrete ones, including alive and unknown patients. For rates, mid-p exact Poisson tests were 
used, comparing non-AIDS and AIDS deaths only. 
4 73 patients did not have a baseline CD4 result 
For continuous variables, pair-wise Wilcoxon rank tests with Holm’s adjustment for multiple 
comparisons were also performed. 
Ref – Reference group 
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 Table 4.2. Groups of specific causes of death 
Groups N % 
AIDS-related 111 49.1 
  Opportunistic 85 37.6 
  Cancer 17 7.5 
  Both 2 0.9 
  Other 7 3.1 
Non-AIDS-related 98 43.4 
  Hepatitis/Liver 8 3.5 
  Infectious 19 8.4 
  Cancer 8 3.5 
  External 11 4.9 
  CVD 9 4.0 
  Other 43 19.0 
Unknown 17 7.5 
CVD – Cardiovascular diseases 
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 Table 4.3. Trends of overall, AIDS-related causes, non-AIDS-related causes and CVD 
death rates per 100 person-years over time for all patients 
 1997-1998 1999-2000 2001-2002 2003-2004 2005-2006 p trend p 1st and Last 1 
Total 4.59 2.96 3.04 3.32 3.08 0.57 <0.01 
AIDS 2.43 1.85 1.76 1.4 1.24 <0.01 0.1 
Non-AIDS 1.89 1.02 1.28 1.4 1.59 0.46 0.2 
CVD 0 0 0.12 0.26 0.35 0.04 0.05 
1 p-value comparing the first (1997-1998) and the last (2005-2006) periods only  
CVD – Cardiovascular diseases considered as either primary or contributing cause of death 
 
 
 
Table 4.4. Models for the hazards of the subdistributions of deaths due to AIDS- and to 
non-AIDS-related causes including baseline age (per 10 year increase), CD4 cell counts 
(per 50 cells increase), gender (reference: female) and risk group (IDU vs. other). 
Baseline age treated as a time-dependent variable. 
Outcome Variables aHR (95% CI) p 
Baseline Age (10 years) 1 1.46 (1.15,1.85) <0.01 
Baseline CD4 (50 cells) 0.87 (0.82,0.92) <0.01 
Male gender 1.07 (0.71,1.59) 0.75 
Deaths due to 
AIDS-related 
causes 
IDU 1.35 (0.42,4.31) 0.61 
Baseline Age (10 years) 2 1.30 (0.94,1.80) 0.12 
Baseline CD4 (50 cells) 0.90 (0.86,0.95) <0.01 
Male gender 0.84 (0.56,1.26) 0.40 
Deaths due to 
non-AIDS-
related causes 
IDU 4.96 (2.34,10.52) <0.01 
1 Negative interaction with time (p = 0.02) 
2 Negative interaction with time (p = 0.77) 
aHR: Adjusted hazard ratio 
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5.1 Abstract 
Losses to follow-up are a major source of bias in cohorts of HIV-infected 
patients, and could lead to mortality underestimation. The authors developed a 
hierarchical deterministic linkage algorithm primarily to be used by cohorts of 
HIV-infected individuals to recover vital status information for patients lost to 
follow-up. Data from patients known to be deceased in two cohorts in Rio de 
Janeiro, Brazil and from the state mortality database between 1999 and 2006 
were used to validate the algorithm. A fully automated procedure yielded a 
sensitivity of 92.9% and 100% specificity when no information was missing. 
When combined with clerical review, in a scenario of 5% death prevalence and 
20% of missing mother’s name, sensitivity reached 96.5%, and specificity, 
100%. In a practical application, the algorithm significantly increased the death 
rates and decreased the rate of loss to follow-up in the cohorts. 
The finding that 23.9% of matched records did not have AIDS as cause 
of death reinforces the need to search all-cause mortality databases and alerts 
for possible underestimation of death rates. These results indicate that the 
algorithm is accurate enough to recover vital status of patients lost to follow-up 
in cohort studies. 
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 5.2 Introduction 
Database linkage is the process of comparing records from different 
databases that contain enough information to determine if these records refer to 
the same person, or more generally, to the same entity [77]. 
There are three main types of record linkage: manual (or clerical), 
deterministic, and probabilistic, which can be combined, depending on the 
strategy used. The first type consists of manually comparing records in two 
databases and deciding if they are true matches or not. This was the standard 
method used before the availability of computers, is often highly labor-intensive, 
and sometimes is not feasible, particularly when the amount of data is too large. 
Deterministic methods are classically based on exact match comparisons of 
either one unique identifier common to both databases (e.g. social security 
number) or a combination of variables that allow unique discrimination (e.g. 
name, surname, date of birth, gender) [78-80]. Probabilistic methods are also 
based on several variables, but comparisons are made based on the prior 
probability of two records belonging to the same entity and then calculating a 
maximum likelihood estimator to reach a score of similarity between records 
[77, 81, 82]. The method to be chosen (or combination of methods) depends on 
the type of analysis to be carried out on the linked data and the types of 
databases available [83]. 
Record linkage is widely used in population-based studies to make 
inferences about specific outcomes and in cohort studies to make inferences at 
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 the level of the individual [79, 83-86]. Morbidity and mortality databases are 
often employed for this purpose, given their wide availability and the fact that in 
general they have enough information to link their records with other databases. 
Cohort studies usually use linkage techniques to gather additional 
information about patients being followed over time. Even cohorts with active 
follow-up tend to complement their information with external databases in order 
to minimize under-reporting of conditions (e.g. vital status), including in their 
protocol a passive follow-up component. In the case of cohorts of human 
immunodeficiency virus (HIV)-infected patients, morbidity databases (e.g. 
tuberculosis, cancer) are also important sources of additional information [87-
89]. 
In Brazil, official surveillance and mortality databases contain variables, 
such as full name, date of birth, and mother’s name (either maiden or married 
last name), that are suitable for linkage procedures, due to their potentially high 
discriminatory power, particularly when used in combinations. 
In the present study, we describe the validation of a new deterministic 
linkage algorithm that we developed to be used for passive data collection for 
cohorts of HIV-infected patients. The algorithm has a hierarchical structure and 
allows for specific errors in names and dates of birth. It can be used in 
combination with clerical review of records that are not classified as true 
matches or as non-matches. The main objectives when developing the 
algorithm were to maximize accuracy and to minimize the need for clerical 
review. 
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 5.3 Materials and methods 
5.3.1 Data sources 
Three data sources were used in this study. The Rio de Janeiro cohort 
database was originally designed to validate the World Health Organization HIV 
staging system in a developing country [90] and currently comprises information 
from 2,666 HIV-infected patients being followed at the Clementino Fraga Filho 
University Hospital in Rio de Janeiro. All patients are aged 16 years or older, 
and are included only if they have at least one follow-up visit. The loss to follow-
up rate between 2000 and 2005 in the Rio de Janeiro cohort was 2.9/100 
person-years. 
The TB-HIV in Rio study (THRio) is an ongoing cohort study designed to 
assess the impact of implementing isoniazid prophylactic therapy for HIV-
positive patients with indication for prophylaxis in Rio de Janeiro. It has enrolled 
more than 15,000 patients from 29 clinics where care is provided both for HIV 
and for tuberculosis [91, 92]. There is still not enough follow-up time to calculate 
accurately the rates of losses to follow-up in this study. 
The third database is the Rio de Janeiro State mortality database from 
2000 through 2006 with a total of 835,066 records. The Rio de Janeiro State 
mortality database is part of the “Sistema de Informação sobre Mortalidade” 
database, which is the official mortality system in Brazil. The death certificate is 
a standardized form that is filled out by a physician, and includes demographic 
information and primary, secondary, and contributing causes of death according 
to the International Classification of Diseases, among other variables. An 
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 electronic version of these forms was introduced country-wide in 1979. 
Information that can identify patients, such as name, mother’s name, date of 
birth and address is also recorded and was made available through a special 
request to the State Health Department. According to the Brazilian Ministry of 
Health, the mortality system in Rio de Janeiro State has coverage of 100% of 
the deaths [93], even though the percentage of undefined causes of death 
remain somewhat high (9.3%) in 2005. 
Data linkage between both cohort databases and the mortality database 
is part of routine procedures for assessment of vital status among patients who 
are lost to follow up and was approved by the institutional review boards of all 
involved institutions. Data from patients known to be dead through an 
independent source (medical charts in general) with identifying variables were 
used for validation purposes. 
To validate the algorithm, test datasets were assembled and then linked 
with the mortality database and the outcome ‘finding a record in the mortality 
database’ was studied. To determine the sensitivity of the linkage to the 
mortality database for identifying deceased patients, all patients known to be 
dead and who had complete information on full name, date of birth and mother’s 
name (either maiden or married last name) in the Rio de Janeiro cohort 
between 2000 and 2005 (53 patients) and in the THRio cohort between 2003 
and 2006 (315 patients) were included in the analysis. 
To assess specificity, we incorporated into the test database records that 
were not supposed to be in the State mortality database between 2000 and 
2006 and that would be subject to similar typing mistakes as the patients known 
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 to be dead. We chose to use a random sample of control records of patients 
who died in 1999, a year that was not included in the linkage. 
The overall completeness of information for the THRio cohort is 98.3% 
for full information and 99.7% for name and date of birth. In the Rio de Janeiro 
cohort, 60% had full information and 100% had at least name and date of birth. 
5.3.2 Data pre-processing 
The first step in data linkage was pre-processing of data to guarantee 
that all variables conformed to the same format. For names, all letters were 
capitalized, and accents and characters other than letters were removed. Last 
names that denoted the same name such as the individual’s father (e.g. ‘Junior’, 
‘Filho’, etc) were also removed. A specific function (see supplementary data) 
was developed for this purpose and has the ability to pre-process a string field 
as a whole, either with Windows-based Latin alphabet encoding (cp1252) and 
DOS-based alphabet, still used in older “.dbf” files (cp850). 
5.3.3 Linkage algorithm 
To avoid an exponential growth of the processing time, records were first 
blocked by a phonetic code (PC) adapted from the original Soundex algorithm 
[94] to account for Brazilian Portuguese names (see supplementary data for 
details). Blocks were composed by the combination of either the PC from first 
and last name together, or the PC from first and last mother’s name, or the PC 
of first name and first mother’s name. This last category was employed to 
account for last names that are difficult to spell and that are recorded equally for 
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 the individual and his/her mother in both databases, but are misspelled in one of 
them. 
Records within each block were then compared, using exact 
comparisons and also allowing for some errors, in a hierarchical fashion, as 
described below. Errors in name fields were evaluated by the PCs and also by a 
string similarity score, based on a recursive longer common substring algorithm, 
implemented in the ‘difflib’ library from the programming language Python [95]. 
Dates of birth were allowed to have at most one digit mistake in any position or 
the common swap between day and month (only if they are exactly the same, 
but swapped). Score values used in the algorithm as described in Table 5.1 
were chosen empirically in the beginning of the algorithm development, using 
different data sources [municipal surveillance databases of acquired 
immunodeficiency syndrome (AIDS) and Tuberculosis – data not shown]. The 
combinations of these measurements and the values for the scores determine 
several levels of inclusion – which in the present paper are referred to as 
‘automatic codes’ and depend on how much information is available, as shown 
in Table 5.1. Records with complete information (automatic codes 0 through 7, 
Table 5.1) are treated independently from records with missing data (automatic 
codes 8 through 10 when mother’s name is missing, Table 5.1). Whenever a 
pair of records is neither automatically included with one of the inclusion codes 
described nor automatically excluded with the criteria in Table 5.1, this pair is 
kept in the final merged database, marked as an unresolved pair for possible 
further clerical review. The algorithm is hierarchical in the sense that lower 
codes mean more similar records – 0 and 8 are perfect matches, but codes 0 
through 7 are used for records with full information, and thus are more robust 
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 than codes 8 through 10 for records that miss mother’s name. The algorithm is 
not ‘greedy’ in that the same record in the test database linked with a 0 code to 
one record could also be linked to another one with a code 7, for example. This 
feature is important, because the algorithm can also be used for databases with 
one-to-many relationships, as is the case of tuberculosis surveillance 
databases. For mortality, which is supposed to have a one-to-one relationship 
with the cohort databases multiple matches for the same patient can easily be 
resolved by automatically picking the match with the lowest value, which was 
done in the present study. 
If a pair was neither included nor excluded, it was eligible for clerical 
review. For records with name only, only perfect matches were considered. 
The algorithm was written in Python for Windows [95]. 
5.3.4 Algorithm validation 
We used three different scenarios to validate the algorithm. First we 
considered a hypothetical situation in which patients lost to follow-up in a cohort 
of HIV-infected patients would be searched in the mortality database and we 
assumed that 50% of these lost patients had actually died. Thus, we 
constructed a database by combining the 368 records of patients known to be 
deceased in the cohorts with a random sample of 368 records from the 1999 
mortality database. In this scenario we compared the accuracy for perfect 
match between the records in all fields with the automatic inclusion codes, 
when: i) full information is available for all individuals; ii) only name and date of 
birth are available; and iii) only name is available. In the second scenario, we 
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 tested the impact on accuracy if all patients in a cohort of HIV infected patients 
were linked to the mortality database, considering that only 5% of the patients 
were truly dead, a reasonable percentage for an open cohort of HIV-infected 
individuals in developing countries, where death rates are generally around 5 
per 100 person-years [1]. In this case we made up a dataset with 368 records of 
patients known to be deceased in the cohorts and by randomly selecting 
368/0.05 – 368 = 6,992 patients from the 1999 mortality database. In these two 
scenarios, ties were resolved automatically by choosing the pair with the lowest 
score and no manual search was performed – the aim being merely to assess 
the potential impact on accuracy of missing information in the test database. 
In the third scenario, we mimic a situation similar to what one may 
encounter in practical research with a cohort of HIV-infected patients: assuming 
50% prevalence of deaths among patients lost to follow-up and 20% of records 
missing mother’s name. The database was set up for this scenario the same 
way as it was for the first scenario, but 20% of mother’s names were randomly 
deleted from the test database. In this run, we did not consider records missing 
date of birth. Unresolved pairs were submitted to clerical review by two 
independent researchers, and disagreements were resolved by a third reviewer. 
Also, records with automatic inclusion codes were manually reviewed for quality 
control purposes. To minimize selection bias, reviewers had no access to the 
group membership status of records being reviewed. 
Sensitivity, specificity, positive predictive (PPV) and negative (NPV) 
values were calculated for the experiments along with 95% confidence intervals 
(CI), using appropriate methods [96]. The total number of records in the test 
databases was used as the denominator for calculations. 
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 For records of patients found in the mortality system, we assessed the 
proportion of cases where AIDS-related ICD-10 codes (B20-B24) were not 
mentioned on the death certificate. The coding system for death certificates 
follows the WHO guidelines [60]. 
For a preliminary practical application of the algorithm, rates of loss to 
follow-up are compared before and after the algorithm is used for the Rio de 
Janeiro cohort and death rates before and after the algorithm is used for both 
cohorts. Exact Poisson 95% confidence intervals (CI) are presented for the 
differences. Calculations were done in the R software environment [61]. 
 
5.4 Results 
The first two scenarios to assess the impact of missing information on the 
accuracy of the algorithm are summarized in Table 5.2. As expected, sensitivity 
for exact matches increases when less information is available to link the 
records, while the addition of the automatic codes without manual review 
represented a significant increase both when full information is available (from 
50.8% to 92.9%) and when mother’s name is missing (71.2% to 91.8%). 
Specificity for both cases was very high and no misclassification was made by 
the algorithm when the death prevalence was 50% (PPV = 100%). In order to 
compare the impact of having 5% or 50% of prevalence, PPV and NPV were 
compared in these two scenarios. While PPV was 100% at 50% prevalence and 
no misclassifications occurred, it was reduced, as expected, at 5% prevalence. 
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 Even though the percentages of automatic codes with full information and 
missing mother’s name are still high (99.4% and 92.6%, respectively), these 
represented two false positive cases in the first instance, and 27 in the second. 
Accuracy for records with patients’ names only was not as good as with the 
other variables; even when considered exact matches only (Table 5.2, last 
column), since sensitivities were lower than automatic codes for the other 
situations. Specificity in this case was very low, with PPV of only 81.2% in the 
50% scenario, yielding 66 false-positive cases, and as low as 19.5% in the 5% 
scenario reaching 1,175 false-positive cases. 
In reference of records to be manually checked, 1,189 of those with full 
information and 4,146 of those with missing mother’s name would have to be 
searched for a prevalence of 50%, and 9,351 and 48,333 for a prevalence of 
5%, respectively. 
In the third scenario with 50% prevalence and 20% of the records 
missing mother’s name, the results obtained were: sensitivity: 96.5%, 95%CI: 
94.0, 98.1; specificity: 100%, 95%CI: 99, 100; positive predictive value: 100%, 
95%CI: 99.0, 100; negative predictive value: 96.6%, 95%CI: 94.2, 98.2. Manual 
review was performed on the 1,929 pairs that the algorithm was not able to 
include or exclude as a true match. Of those, 9 pairs were considered true 
matches for reviewer #1 and 11 for reviewer #2. The two disagreements were 
submitted to a third reviewer, who considered one of them a true match. Manual 
review of the automatic codes considered all of them true matches.  
The combination of automatic codes and clerical review yielded high 
sensitivity and specificity, with a PPV of 100% and NPV of 96.6% for this test 
database. 
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 Among the 355 patients who were found by the algorithm, 85 (23.9%) did 
not have HIV-AIDS International Classification of Diseases 10th revision codes 
(B20 – B24) as the underlying cause of death. 
Before the algorithm was used, the rate of loss to follow-up in the Rio de 
Janeiro cohort between 2000 and 2005 was 2.9/100 person-years and it 
dropped to 2.1/100 person-years after recovery from the mortality system 
(difference = -0.8, 95%CI: -1.1,-0.6). In the same period the mortality rate was 
raised with the deaths from the mortality system from 2.2/100 person-years to 
3.2/100 person-years (difference = 1.0, 95%CI: 0.7,1.3). For THRio, the death 
rate in 2006 before the use of the algorithm was 1.2/100 person-years and 
increased to 4.2/100 person-years after deaths were recovered for all patients 
in the cohort, using automatic codes only, without manual review (difference = 
3.0, 95%CI: 2.7,3.3). 
5.5 Discussion 
The deterministic algorithm validated in the present study was developed 
primarily to assist cohorts of HIV-infected patients with active follow-up to 
improve their performance by searching for patients lost to follow-up in mortality 
databases. The performance characteristics of the algorithm were excellent, 
with a sensitivity of over 90% for automatic codes, either in the 5% or in the 
50% prevalence scenarios, which was minimally affected when mother’s name 
was not available. These figures were well over the sensitivity for exact matches 
of 50% and 71% when full information was available and mother’s name was 
missing, respectively. Specificity was close to 100% for all cases, meaning that 
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 not a single pair was misclassified as a false-positive, but when considering 
records with patient’s names only, even for exact matches specificity was 
unacceptably low (around 82%). These results are in agreement with the study 
by Quantin et al. [97], who found that date of birth and first and last patient’s 
name would have enough discriminating power, even though their study was 
carried out using a probabilistic approach and they did not test mother’s name 
as one of the variables. In the 5% scenario, the PPV remained close to 100% in 
all situations, and there were two false-positives in the full information dataset 
and an excess of 27 when mother’s name was missing, indicating that, even 
though false-positives are very unlikely (PPV = 98.9% and 92.5%, respectively), 
caution must be taken when assigning a patient as being deceased. 
In the third scenario, with 50% prevalence and having 20% of the records 
missing mother’s name with clerical review increased sensitivity to over 96%, 
while preserving 100% specificity. 
Although sensitivity was high, it was still impossible to find 13 patients 
reported as deceased in medical charts. Two situations may have concurred for 
this finding: i) patients indeed were not included in the mortality database or ii) 
patients were in the database but the algorithm was not able to find their 
records. In the former case, if the patient is in fact still alive he/she is truly lost to 
follow up. On the other hand, if the patient is indeed deceased, either the event 
was not detected by the system or the patient moved out of the state and died 
elsewhere. In the case of patients who are in the mortality database, the main 
reasons for not finding a record are major spelling errors – especially for the first 
letter, which is very sensitive to Soundex-like phonetic algorithms, but also 
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 deletion of the last name in the case of individuals with four or more names – 
and incorrectly entered dates of birth. 
The amount of records left for manual review suggest that the best option 
is to pre-select records to be linked to the databases in order to increase the 
number of patients that are supposed to be found, decreasing clerical review. 
Even though probabilistic algorithms have been extensively studied and 
there is at least one algorithm validated for Brazilian databases [98, 99], we 
chose to use a deterministic approach, allowing for some uncertainty on the 
variables used. This decision was based on the fact that even though 
probabilistic algorithms tend to yield higher sensitivities, they do so by 
sacrificing specificity, which is not a major problem when studying population-
based characteristics, given false-positives and false-negatives would tend to 
cancel out [83, 100]. Conversely, to infer the vital status of individual patients 
being followed in a cohort, this approach is not advisable and deterministic 
algorithms are more indicated [83], given that ethical problems may emerge 
once his or her vital status is declared to be deceased and the patient shows up 
for a subsequent visit. In either case, caution should always be exercised since 
bias due to false-positives and negatives, would lead to over- or 
underestimation of the parameters being studied, although the impact of false-
positives on overestimation tends to be more severe than of false-negatives on 
underestimation [100]. 
One of the reasons that cohorts with active tracing of patients might 
suffer from losses to follow-up is that information on deaths that occur in other 
health care units might be out of reach for the clinic where routine care is 
provided, especially if the cause of death was not related to AIDS. In cohorts of 
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 patients who are intrinsically prone to high morbidity and/or mortality rates, as is 
the case of cohorts of HIV-infected patients, this can be particularly problematic. 
For example, in a study involving 6,498 patients being followed in 18 treatment 
programmes in lower income countries, the estimated death rate one year after 
initiation of antiretroviral therapy would increase from 6.4 to 15 per 100 person-
years if mortality among loss to follow-up was similar to that observed in patient 
without antiretroviral therapy [1]. In another report from cohorts in Sub-Saharan 
countries, 41% of patients had unknown vital status on medical charts and 65% 
of those, initially considered to be lost to follow-up, were found to be dead after 
appropriate vital status investigation procedures were applied [101]. 
A practical application of the algorithm in both cohorts showed very good 
results. In THRio, applying the algorithm for all patients with the 2006 mortality 
database, there was a significant increase in the death rate for that year, even 
using automatic codes only. For the Rio de Janeiro cohort, the impact of the 
algorithm on patients lost to follow-up was significant both in reducing losses to 
follow-up and increasing death rate for the period of 2000-2005. 
Finally, the fact that almost 24% of the death certificates of cases that 
were found through our algorithm did not have AIDS International Classification 
of Diseases 10th revision codes mentioned on them (B20-B24) underscores the 
need to search in all-mortality databases and not to restrict searches to 
HIV/AIDS deaths. On the other hand this finding suggests that official HIV/AIDS 
mortality figures that are based solely on the mortality system might significantly 
underestimate the true figures, a possibility that should be formally evaluated, 
which might lead to adjustments in mortality statistics in Brazil. 
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 5.6 Tables 
Table 5.1. Classification of Matched Records 
Inclusion codes 
a 
Patient’s name Date of birth Mother’s name b 
0 Exact Exact Exact 
1 Exact Exact Same PC 
2 Exact 1 error or swap Exact 
3 Exact 1 error or swap Same PC 
4 Score>0.75 Exact Exact 
5 Score>0.75 1 error or swap Exact 
6 Score>0.75 Exact 
Same PC + 
score>0.75 
7 Score>0.9 1 error or swap Score>0.8 
8 Exact Exact Missing 
9 Exact 1 error or swap Missing 
10 Score>0.9 Exact Missing 
Not missing > 1 error Different PC 
Score<=0.9 > 1 error Score<=0.8 
Not missing > 1 error Score<=0.7 
Score<0.8 Not missing Not missing 
Not missing 
Day, month and 
year are different 
Missing 
Exclusion c 
Score<0.8  Missing 
PC, phonetic code; a After passing the first blocking phase: same PC of first and last patient’s 
name OR same PC of first and last mother’s name OR same PC of patient and mother first 
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names; b PC is for mother’s name only in this case; c Records that are not included nor excluded 
are left over for clerical review. Score values were chosen empirically (please see text). 
 
 Table 5.2. Summary Accuracy Measures and 95% Confidence Intervals for Exact Matches and Automatic Codes When Records in the Test 
Database Have Full or Partial Information, in Two Hypothetical Prevalence Scenarios: 50% and 5% 
 Full Information No mother’s name Name only a 
Accuracy Exact match b Automatic codes c Exact match b Automatic codes c Exact match b 
 % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI 
Sensitivity 50.8 45.6, 56.0 92.9 88.3, 94.2 71.2 66.3, 75.8 91.8 88.6, 94.4 77.4 72.8, 81.6 
Specificity 100.0 99.0, 100.0 100.0 99, 100.0 100.0 99.0, 100.0 100.0 99.0, 100.0 82.1 77.8, 85.8 
PPV (50% 
prevalence) 
100.0 98.0, 100.0 100.0 98.9, 100.0 100.0 98.6, 100.0 100.0 98.9, 100.0 81.2 76.7, 85.1 
NPV (50% 
prevalence) 
67.0 62.9, 70.9 93.4 90.5, 95.6 77.6 73.6, 81.3 92.5 89.4, 94.9 78.4 74.0, 82.4 
PPV (5% prevalence) 100.0 98.0, 100.0 99.4 97.9, 99.9 98.9 96.7, 99.8 92.6 89.4, 95.0 19.5 17.5, 21.6 
NPV (5% prevalence) 97.5 97.1, 97.8 99.6 99.5, 99.8 98.5 98.2, 98.8 99.6 99.4, 99.7 98.6 98.3, 98.9 
CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value 
a Since only name was available in this case, only exact matches were considered; b Exact match means perfect match between the 
available variables in both databases; c The codes listed in Table 5.1 
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6.0 CONCLUSIONS 
Temporal changes of causes of death among HIV-infected individuals have been 
reported in developed countries in the HAART era. Several studies in developed 
countries have documented these changes, showing that, although HIV/AIDS-related 
causes of death remain the most common cause of death, other conditions, including 
diabetes mellitus, cardiovascular disease, cancer, liver and renal diseases have been 
increasingly reported in HIV-infected individuals [5-9]. In Brazil, where access to HAART 
has been universal for all patients who qualify since 1996, a steep decrease in mortality 
among HIV/AIDS patients has been documented, but the rates have been fairly stable 
between 1999 and 2004 [3, 4]. However, no data are available about the pattern of 
mortality in these patients. In this study, we investigated the profile of non-HIV-related 
causes of death in HIV-infected patients in Brazil, both in the population and individual 
level, resulting in three papers as described below. 
In the first paper we used the Brazilian mortality database from 1999 to 2004 and 
showed that in Brazil, similar to what has been reported from developed countries, 
mortality patterns among HIV/AIDS patients are changing in the HAART era. We found 
that, in comparison to 1999, there was a steady and significantly larger increase in the 
frequency with which conditions not usually associated with HIV/AIDS were listed as 
causes of death for individuals who also had HIV listed on the death certificate 
  
 compared to individuals who did not, from 16.3% in 1999 to 24.1% in 2004, 
representing 14,746 deaths in the period. In particular, listing of cardiovascular diseases 
or diabetes mellitus as causes of death represented 3,746 and 744 deaths, respectively, 
both appearing to become more likely causes of death over time in individuals whose 
death certificate also included HIV/AIDS than in those who did not. Additionally, during 
the same period there were statistically significant increases in these conditions as 
underlying causes of death among individuals who had HIV/AIDS mentioned on their 
death certificates. To our knowledge, this is the first paper that documents this transition 
in Brazil. 
In the second paper, we showed that overall mortality rates in a large cohort of 
HIV-infected patients in Rio de Janeiro, Brazil, remained fairly stable between 1999 and 
2006, in accordance with what has been described in Brazil and the results of the first 
paper. However, when AIDS- and non-AIDS-related causes of death are examined 
separately, though, a different picture emerged, with a decrease in AIDS-related causes 
of death (from 2.43/100 py in 1997-1998 to 1.24/100 py in 2005-2006; p < 0.01) and an 
increase in non-AIDS-related causes of death. Although the temporal trend for non-
AIDS-related causes of death did not reach statistical significance, by 2005-2006 non-
AIDS-related causes of death were more frequent than AIDS-related causes of death 
(1.59/100 py and 1.24/100 py, respectively). There was also an increase of CVD as a 
cause of death (p = 0.04). In corroboration, when more restrictive criteria to classify 
causes of death were used, non-immunodeficiency related causes of death increase 
over time. Baseline age was associated with risk for AIDS-related causes of death, but 
the risk decreased over time. However, it had no significant effect on non-AIDS related 
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 causes of death, indicating that, as patients age because of longer survival, they 
become at higher risk of dying from a non-AIDS related cause of death. These findings 
were in accordance with the recent description of HIV cohorts tending to get older [63], 
as is the case in our cohort, where the median age significantly increased from 33.25 
years in 1997 to 39.0 years in 2006 (p < 0.01). 
The results described in the second paper were facilitated by a linkage algorithm 
that was created for this project to recover vital status from patients who were lost to 
follow-up. As a result, the use of this algorithm increased the observed mortality rate 
from 2.0/100 py to 3.2/100 py (difference = 1.2; 95%CI = 0.9,1.4; p < 0.01) after patients 
considered lost to follow-up were matched with the mortality database. We developed 
and validated this hierarchical deterministic algorithm as part of this study to compare 
records between databases that do not have unique identifiers, using name, date of 
birth and mother’s name as the linking variables. The validation of the algorithm was 
presented in a third paper. The results demonstrated a sensitivity over 95% and 
specificity of nearly 100% for the outcome of finding a record in the mortality database. 
A practical application of the algorithm was described in this paper both in the Rio de 
Janeiro cohort and in THRio (see Section 5.3.1 for description). In both cases there was 
a significant increase in death rates (difference = 1.0, 95%CI: 0.7,1.3 and difference = 
3.0, 95%CI: 2.7,3.3, respectively). In the Rio de Janeiro cohort, between 2000 and 2005 
the loss-to-follow-up rate dropped from 2.9/100 person-years to 2.1/100 person-years 
after recovery from the mortality system (difference = -0.8, 95%CI: -1.1,-0.6). 
In conclusion, these are the first studies to examine changes in mortality patterns 
among HIV-infected individuals in the HAART era in Brazil. Conditions that potentially 
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 may be prevented and/or treated, such as CVD and DM appear to have become more 
common causes of death over time among HIV-infected individuals than in the general 
population when death certificates data was studied. The major driving force behind the 
observed increase in deaths from non-AIDS related causes appears to be longer 
survival due to the substantial decrease in deaths due to AIDS-related causes. 
These findings have major public health and programmatic implications for developing 
countries that are providing access to HAART. The clinical management of persons 
living with HIV/AIDS in Brazil needs to be expanded to include prevention, diagnosis, 
and treatment of chronic conditions such as CVD and DM. Successfully managing non-
AIDS related conditions will require the integration of HIV/AIDS programs with other 
public health programs, such as smoking cessation and control of hypertension [57]. 
Finally, for other developing countries that are just starting to scale-up their programs, 
lessons learned from the Brazilian experience might help to prepare in advance to 
changes in morbidity and mortality patterns that will likely occur once HAART becomes 
widely available. 
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 APPENDIX A. Linkage algorithm code (PYTHON) 
#---------------------------------------------------------------------------- 
# Name:        supplemental.py 
# Purpose:     Supplemental material for the manuscript 'Validation of a  
#              hierarchical deterministic record linkage algorithm using  
#              data from two different cohorts of HIV-infected individuals 
#              and mortality databases in Brazil' from Pacheco, AG et al. 
#              Presents functions, lists and blocks written in Python that 
#              implement the algorithm validated in the manuscript. 
#               
# 
# Author:      Antonio Guilherme Pacheco 
# 
# Created:     2008/02/19 
# Copyright:   (c) 2008 
# Licence:     GPL 
#---------------------------------------------------------------------------- 
 
 
# -*- coding: cp1252 -*- 
import traceback 
from difflib import * 
from datetime import * 
 
 
""" 
This file contains a collection of functions and lists used in the linkage 
algorrithm. 
Actual implementation needs further programming, but it is readily extensible 
in Python. 
""" 
 
""" 
Part 1: Data pre-processing. Lists for conversion of non-ASCII characters 
into ASCII characters 
considering both cp1252 and cp850 coding pages. 
""" 
 
#cp1252 
caracteres_cp1252={ 
u'Ç':'C', 
u'Á':'A', 
u'À':'A', 
u'Ã':'A', 
u'Ä':'A', 
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 u'Â':'A', 
u'É':'E', 
u'È':'E', 
u'Ë':'E', 
u'Ê':'E', 
u'Í':'I', 
u'Ì':'I', 
u'Ï':'I', 
u'Ó':'O', 
u'Ò':'O', 
u'Õ':'O', 
u'Ö':'O', 
u'Ô':'O', 
u'Ú':'U', 
u'Ù':'U', 
u'Ü':'U', 
u'Ñ':'N', 
u"'":'', 
u'"':'', 
u'`':'', 
u'.':'', 
u'=':'', 
u';':'', 
u'/':'', 
u'\\':'', 
u'+':'', 
u'-':'', 
u'(':'', 
u')':'', 
u'*':'', 
u']':'', 
u'[':'', 
u'#':'', 
u'~':'', 
u':':'', 
u'\x8a': 'ARIA', 
u'\xc1': 'A', 
u'\xc0': 'A', 
u'\xc3': 'A', 
u'\xc2': 'A', 
u'\xc4': 'A', 
u'\xc9': 'E', 
u'\xc8': 'E', 
u'\xcb': 'E', 
u'\xca': 'E', 
u'\xcd': 'I', 
u'\xcc': 'I', 
u'\xcf': 'I', 
u'\xce': 'I', 
u'\xd3': 'O', 
u'\xd2': 'O', 
u'\xd5': 'O', 
u'\xd4': 'O', 
u'\xd6': 'O', 
u'\xd9': 'U', 
u'\xdb': 'U', 
u'\xda': 'U', 
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 u'\xb4':''} 
 
#cp850 
caracteres_cp850={ 
u'Ç':'C', 
u'Á':'A', 
u'À':'A', 
u'Ã':'A', 
u'Ä':'A', 
u'Â':'A', 
u'É':'E', 
u'È':'E', 
u'Ë':'E', 
u'Ê':'E', 
u'Í':'I', 
u'Ì':'I', 
u'Ï':'I', 
u'Ó':'O', 
u'Ò':'O', 
u'Õ':'O', 
u'Ö':'O', 
u'Ô':'O', 
u'Ú':'U', 
u'Ù':'U', 
u'Ü':'U', 
u'Ñ':'N', 
u"'":'', 
u'"':'', 
u'`':'', 
u'.':'', 
u'=':'', 
u';':'', 
u'/':'', 
u'\\':'', 
u'+':'', 
u'-':'', 
u'(':'', 
u')':'', 
u'*':'', 
u']':'', 
u'[':'', 
u'#':'', 
u'~':'', 
u':':'', 
u'!':'', 
u'|':'', 
u'\xd8': 'U', 
u'\u0131': 'O', 
u'\u2550': 'I', 
u'\u0131': 'O', 
u'\u2566': 'E', 
u'\u250c': 'A', 
u'\u2569': 'E', 
u'\u0131': 'ARIA ', 
u'\u2534': 'A', 
u'\xe3': 'A', 
u'\xe9': 'U', 
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 u'\u2560': 'A', 
u'\xe0': 'O', 
u'\xef': '', 
u'\u252c': 'O', 
u'\u253c': 'O', 
u'\u251c': 'O', 
u'\xa4': '', 
u'\u2514': 'O', 
u'\u2554': 'U', 
u'\xc5':'O', 
u'\xf2':'A', 
u'\xb4':'', 
u'\xe5':'O', 
u'\u2563':'A', 
u'\u2524':'', 
u'\u2557':'A', 
u'\xa6':'ARIA ', 
u'\xba':'ARIA ', 
u'\xaa':'ARIA'} 
 
def limpa_caracter(string, code='latin1'): 
    """ 
    Turns non-ASCII characters into ASCII characters. Should be used  
    BEFORE applying soundex algorithm 
    """ 
    string1='' 
    if string==None or string=='': 
        return '' 
    elif code=='latin1': 
        string=unicode(string.upper(), 'latin1') 
        for s in string: 
            if s in caracteres_cp1252.keys(): 
                string1=string1+caracteres_cp1252[s] 
            else: 
                string1=string1+s 
    elif code=='dos': 
        string=unicode(string.upper(), 'cp850') 
        for s in string: 
            if s in caracteres_cp850.keys(): 
                string1=string1+caracteres_cp850[s] 
            else: 
                string1=string1+s 
    return string1 
 
 
""" 
Part 2: Modified Soudex: Soundex algorithm modified for Brazilian Protuguese 
spelling 
""" 
 
#Last names to be excluded: 
nome_exclui=[ 
'JUNIOR' 
'JR', 
'FILHO', 
'I', 
'II', 
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 'III', 
'F'] 
 
#Modified Soundex coding system: 
letra_cod={ 
u'A':'0', 
u'E':'0',  
u'H':'0',  
u'I':'0', 
u'O':'0', 
u'U':'0', 
u'Y':'0', 
u'S':'0', 
u'0':'0', 
u'B':'1', 
u'F':'1', 
u'P':'1', 
u'V':'1', 
u'W':'1', 
u'C':'2', 
u'G':'2', 
u'J':'2', 
u'K':'2', 
u'Q':'2', 
u'S':'2', 
u'X':'2', 
u'Z':'2', 
u'D':'3', 
u'T':'3', 
u'L':'4', 
u'M':'5', 
u'N':'5', 
u'R':'6'} 
 
#Conversion of (possible) non-ASCII characters (not used if pre-processed 
names are used) 
conv_simb={ 
u'Ç':'2', 
u'Á':'0', 
u'À':'0', 
u'Ã':'0', 
u'Ä':'0', 
u'Â':'0', 
u'É':'0', 
u'È':'0', 
u'Ë':'0', 
u'Ê':'0', 
u'Í':'0', 
u'Ì':'0', 
u'Ï':'0', 
u'Ó':'0', 
u'Ò':'0', 
u'Õ':'0', 
u'Ö':'0', 
u'Ô':'0', 
u'Ú':'0', 
u'Ù':'0', 
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 u'Ü':'0'} 
 
#Exclusion of (possible) symbols and letter H (not really a consonant in 
Portuguese) 
 
simb_exclui=[ 
u'H', 
u'', 
u' ', 
u',', 
u"'", 
u'"', 
u'\xb4', 
u'\xa4', 
u'`', 
u'-', 
u'_', 
u'\\', 
u'0', 
u'1', 
u'2', 
u'3', 
u'4', 
u'5', 
u'6', 
u'7', 
u'8', 
u'9', 
u'#'] 
 
#Function to find first name in a string 
def find_pnome(nome): 
    """ 
    Finds first name 
    """ 
    if ' ' not in nome: 
        return '0000' 
    else: 
        pnome=nome[0] 
        i=1 
        while nome[i] != ' ': 
            pnome=pnome+nome[i] 
            i+=1 
        return pnome.upper() 
 
 
#Function to find last name in a string 
def find_snome(nome): 
    """ 
    Finds last name 
    """ 
    if ' ' not in nome: 
        return '0000' 
    else: 
        i=len(nome)-1 
        snome='' 
        while nome[i] != ' ': 
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             snome=nome[i]+snome 
            i-=1 
        return snome.upper()     
 
         
def nome_2_code(nome, tam=4): 
    """ 
    Turns a single name (first or last) into modified soundex code 
    """ 
    try: 
        nome=unicode(nome.upper(),'cp1252') 
    except TypeError: 
        nome=nome.upper() 
    if nome[0] not in simb_exclui: 
        codigo=nome[0] 
        i=1 
    else: 
        codigo=nome[1] 
        i=2 
    if codigo=='W': 
        codigo='V' 
    elif codigo=='K': 
        codigo='C' 
    elif codigo=='Y': 
        codigo='I' 
    elif codigo=='J' and (nome[i]=='I' or nome[i]=='E'): 
        codigo='G' 
    nome=nome[i:] 
    for x in range(1,len(nome)): 
        if nome[x-1] not in simb_exclui and nome[x-1]!=nome[x]: 
            if nome[x-1] in conv_simb.keys(): 
                codigo+=conv_simb[nome[x-1]] 
            else:         
                codigo+=letra_cod[nome[x-1]] 
    codigo=codigo.replace('0','') 
    return (codigo + (tam*'0'))[:tam] 
 
 
def acha_soundex(nome): 
    """ 
    This binding function finds first and last names, get their modified 
    soundex codes and combines them in a single string, e.g u'N420S410'. 
    """ 
    if ' ' not in nome: 
        return '00000000' 
    else: 
        pnome=find_pnome(nome) 
        snome=find_snome(nome) 
        if len(pnome)==1 or len(snome)==1: 
            return '00000000' 
        else: 
            while nome_exclui.__contains__(snome) or 
simb_exclui.__contains__(snome): 
                nome=nome[:len(nome)-len(snome)-1] 
                snome=find_snome(nome) 
            return nome_2_code(pnome) + nome_2_code(snome) 
 
 82 
  
""" 
Part 3: Main functions of the algorithm (uses Part 2 functions as well) 
""" 
 
def cria_soundex(match): 
    """ 
    Takes a list of lists in which mother's name is in the last position 
    and patient's name in the third position from the last. Allows other 
    variables to be in any other positions (in general second position from 
    the last is date of birth, but no necessarily here). Returns a list of  
    lists with 3 elements: soundex of first and last patient's name, soundex 
    of first and last patient's mother's name and soundex of first names of 
    both patient and mother, combined in a single string, 
    e.g. [u'N420S410', u'L500S410', u'N420L500']. The resulting list can be 
    used for blocking and is also used in the main function below. 
    """ 
    recs=[] 
    for m1 in match: 
        try: 
            recs.append([acha_soundex(m1[-3].strip()), acha_soundex(m1[-
1].strip()), acha_soundex(find_pnome(m1[-3].strip())+' '+find_pnome(m1[-
1].strip()))]) 
        except: 
            recs.append([]) 
            print m1[-3].strip(), m1[-1].strip() 
            print traceback.print_exc( ) 
         
    return recs 
 
 
def monta_data(dia, mes, ano): 
    """ 
    Auxiliary function to set up a date when comparing number by number 
    """ 
    dia=str(dia) 
    mes=str(mes) 
    ano=str(ano) 
    if ano=='9999' or ano=='None' or dia=='99' or mes=='99': 
        return None 
    if len(mes)==1: 
        mes='0'+mes 
    if len(dia)==1: 
        dia='0'+dia 
    return str(ano) +  str(mes) +  str(dia) 
 
 
def compara_dob(dob1, dob2): 
    """ 
    Compares two dates in datetime format and returns scores, depending on 
    the similarity between them - 0 no match; 1 perfect match; 2 day/month 
    swap; 3 at most 1 error in any position 
    """ 
    if dob1==dob2: 
        return 1 
    else: 
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         if dob1.year==dob2.year and dob1.month==dob2.day and 
dob2.month==dob1.day: 
            return 2 
        else: 
            score=0 
            dob11=monta_data(dob1.day,dob1.month,dob1.year) 
            dob21=monta_data(dob2.day,dob2.month,dob2.year) 
            for i in range(len(dob11)): 
                if dob11[i]==dob21[i]: 
                    score=score+1 
            if score>=7: 
                return 3 
            else: 
                return 0 
 
 
def cria_level(m): 
    """ 
    Main algorithm function. Takes a single list of (possibly) pre-blocked  
    records from 2 patients in the databases being linked and returns 3 
pieces  
    of information: the linkage level, the string comparison score for 
patient's  
    name and the string comparison score for patient's mother's name. The 
list  
    must be of length 12, being the first 6 from one patient and the last 6 
from  
    the one being compared. These 6 fields are a combination of: full name,  
    date of birth, full mother's name and the list generated with the  
    cria_soundex() function above. 
    """ 
    limiar=0.8 
    level='' 
    sc=SequenceMatcher(lambda x: x == " ", m[0], m[6]).ratio() 
    if m[2]!='' and m[8]!='': 
        sc_mae=SequenceMatcher(lambda x: x == " ", m[2], m[8]).ratio() 
    else: 
        sc_mae=0 
    if m[1]!=None and m[2]!='' and m[7]!=None and m[8]!='': 
        if m[0]==m[6] and m[1]==m[7] and m[2]==m[8]: 
            level=0 
        elif m[0]==m[6] and m[1]==m[7] and m[4]==m[10]: 
            level=1 
        elif m[0]==m[6] and compara_dob(m[1],m[7])!=0 and m[2]==m[8]: 
            level=2 
        elif m[0]==m[6] and compara_dob(m[1],m[7])!=0 and m[4]==m[10]: 
            level=3 
        elif m[0]!=m[6] and m[1]==m[7] and m[2]==m[8] and sc>0.75: 
            level=4 
        elif m[0]!=m[6] and compara_dob(m[1],m[7])!=0 and m[2]==m[8] and 
sc>0.75: 
            level=5 
        elif m[0]!=m[6] and m[1]==m[7] and m[4]==m[10] and sc>0.75 and 
sc_mae>0.75: 
            level=6 
        elif compara_dob(m[1],m[7])==0 and m[4]!=m[10]: 
            level=999 
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         elif compara_dob(m[1],m[7])!=0 and sc>0.9 and sc_mae>0.8: 
            level=7 
        elif compara_dob(m[1],m[7])==0 and sc<=0.9 and sc_mae<=0.8: 
            level=999 
        elif compara_dob(m[1],m[7])==0 and sc_mae<=0.7: 
            level=999 
        else: 
            if sc<limiar: 
                level=999 
            else: 
                level=91 
    elif m[1]!=None and m[7]!=None: 
        if m[0]==m[6] and m[1]==m[7]: 
            level=8 
        elif m[0]==m[6] and compara_dob(m[1],m[7])!=0: 
            level=9 
        elif m[1]==m[7] and sc>0.9: 
            level=10 
        elif compara_dob(m[1],m[7])==0 and m[1].year!=m[7].year and 
m[1].day!=m[7].day and m[1].month!=m[7].month: 
            level=999 
        else: 
            if sc<limiar: 
                level=999 
            else: 
                level=92 
    elif m[2]!='' and m[8]!='': 
        if m[0]==m[6] and m[2]==m[8]: 
            level=11 
        elif m[0]==m[6] and m[4]==m[10]: 
            level=12 
        else: 
            level=999 
    else: 
        if sc<limiar: 
            level=999 
        else: 
            level=99 
    return level, sc, sc_mae 
 
             
 
""" 
Part 4: Blocking strategy. If blocking is implemented to speed up 
computational  
time (as it was done in this algorithm) it is done in a separate block, that  
call the above functions. In our case, the 'match1' and 'match2' objects are  
the lists used by the cria_soundex() function and 'sound1' and 'sound2' its  
output for records to be compared in database 1 and database 2, repectively,  
as seen below. 
""" 
 
result=[] 
for i in xrange(len(sound1)): 
    for j in xrange(len(sound2)): 
        try: 
            #Blocking 
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             if sound1[i]!=[] and sound2[j]!=[] and 
(sound1[i][0]==sound2[j][0] or ((sound1[i][1]!='00000000' and 
sound2[j][1]!='00000000') and (sound1[i][1]==sound2[j][1] or 
sound1[i][2]==sound2[j][2]))): 
                #Setting up for cria_level() 
                res=match1[i][-3:]+sound1[i]+match2[j][-3:]+sound2[j] 
                try: 
                    level, score, score_mae=cria_level(res) 
                except: 
                    print res 
                #Discard unmatched pairs 
                if level!=999: 
                    #Setup a combination of variables for output 
                    result.append(match1[i]+match2[j]+[str(level), 
str(score), str(score_mae)]) 
        except: 
            print sound1[i], sound2[j] 
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